<units>
<unit type="BATCH">
<unit-content>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_8</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Therapy-Induced Toxicities Associated with the Onset of Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>Joshua R.</ce:given-name>
</author>
<affiliation>
<organization>Department of Surgery</organization>
<organization>Indiana University School of Medicine</organization>
<organization>Department of Anatomy, Cell Biology and Physiology</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>Fabrizio</ce:given-name>
</author>
<affiliation>
<organization>Department of Anatomy, Cell Biology and Physiology</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="3">
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Otolaryngology – Head and Neck Surgery</organization>
<organization>Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA Department of Otolaryngology – Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
</person>
<affiliation>
<organization>Department of Surgery</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Cancer is the second-leading cause of death worldwide. Notably, 40% of all patients suffer from cachexia, a debilitating muscle wasting syndrome that represents one of the primary causes of death in advanced cancer patients. Despite their known side effects, such as vomiting, anorexia, mucositis, neuropathy, musculoskeletal and metabolic alterations, chemotherapy treatments are the most effective and extensively used strategies against cancer. Moreover, chemotherapeutic agents may participate in and even exacerbate the pathophysiological alterations driving cachexia. Indeed, skeletal muscle atrophy and cardiac abnormalities occurring as a consequence of chemotherapy administration can worsen the response to anticancer therapies, reduce physical activity and severely impede the quality of life in cancer patients. Hence, chemotherapy-induced cachexia has recently emerged as a critical clinical problem impacting outcomes and overall survival in cancer patients. Here, we review some of the mechanism(s) through which chemotherapeutics induce musculoskeletal deficits related to cachexia. Lastly, we discuss different strategies currently under consideration to protect muscle tissue from chemotherapy-related toxicities, including nutritional interventions, mitochondria-targeted molecules, ghrelin, bisphosphonates, ACVR2B antagonists, and physical exercise.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>139</first-page>
<last-page>153</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="157">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2022</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2022"/>
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>33</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., et al.: Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)</ref-fulltext>
<ce:source-text>Siegel, R.L., et al.: Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Arem</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Loftfield</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Lifestyle Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>200</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arem, H., Loftfield, E.: Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. Am. J. Lifestyle Med. 12(3), 200–210 (2018)</ref-fulltext>
<ce:source-text>Arem, H., Loftfield, E.: Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. Am. J. Lifestyle Med. 12(3), 200–210 (2018)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Evolution of cancer pharmacological treatments at the turn of the third millennium</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Falzone</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Salomone</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Libra</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1300</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Falzone, L., Salomone, S., Libra, M.: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018)</ref-fulltext>
<ce:source-text>Falzone, L., Salomone, S., Libra, M.: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment – objectives and quality of life issues</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.A.</ce:initials>
<ce:surname>Khan</ce:surname>
</author>
<author seq="2">
<ce:initials>S.S.</ce:initials>
<ce:surname>Akhtar</ce:surname>
</author>
<author seq="3">
<ce:initials>M.K.</ce:initials>
<ce:surname>Sheikh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Malays. J. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>5</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Khan, F.A., Akhtar, S.S., Sheikh, M.K.: Cancer treatment – objectives and quality of life issues. Malays. J. Med. Sci. 12(1), 3–5 (2005)</ref-fulltext>
<ce:source-text>Khan, F.A., Akhtar, S.S., Sheikh, M.K.: Cancer treatment – objectives and quality of life issues. Malays. J. Med. Sci. 12(1), 3–5 (2005)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of the evolution of cancer treatment therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Arruebo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3279</first-page>
<last-page>3330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arruebo, M., et al.: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3), 3279–3330 (2011)</ref-fulltext>
<ce:source-text>Arruebo, M., et al.: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3), 3279–3330 (2011)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Improving radiotherapy in cancer treatment: Promises and challenges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.H.W.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>M.T.</ce:initials>
<ce:surname>Kuo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>37</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>62742</first-page>
<last-page>62758</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, H.H.W., Kuo, M.T.: Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 8(37), 62742–62758 (2017)</ref-fulltext>
<ce:source-text>Chen, H.H.W., Kuo, M.T.: Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 8(37), 62742–62758 (2017)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Radiation oncology in the era of precision medicine. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Baumann</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>234</first-page>
<last-page>249</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumann, M., et al.: Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 16(4), 234–249 (2016)</ref-fulltext>
<ce:source-text>Baumann, M., et al.: Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 16(4), 234–249 (2016)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Hormonal therapy for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Jacinta Abraham</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Medicine</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>33</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jacinta Abraham, J.S.: Hormonal therapy for cancer. Medicine. 44(1), 30–33 (2016)</ref-fulltext>
<ce:source-text>Jacinta Abraham, J.S.: Hormonal therapy for cancer. Medicine. 44(1), 30–33 (2016)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Current status and future directions of cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1773</first-page>
<last-page>1781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer. 9(10), 1773–1781 (2018)</ref-fulltext>
<ce:source-text>Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer. 9(10), 1773–1781 (2018)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Delivery strategies of cancer immunotherapy: Recent advances and future perspectives</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Hematol. Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, Z., et al.: Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J. Hematol. Oncol. 12(1), 126 (2019)</ref-fulltext>
<ce:source-text>Zhao, Z., et al.: Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J. Hematol. Oncol. 12(1), 126 (2019)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Alkylating Agents, in Livertox: Clinical and Research Information on Drug-Induced Liver Injury</ref-titletext-english>
</ref-title>
<ref-publicationyear first="2012"/>
<ref-text>Bethesda (MD)</ref-text>
</ref-info>
<ref-fulltext>Alkylating Agents, in LiverTox: Clinical and research information on drug-induced liver injury. 2012: Bethesda (MD)</ref-fulltext>
<ce:source-text>Alkylating Agents, in LiverTox: Clinical and research information on drug-induced liver injury. 2012: Bethesda (MD)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Lansiaux</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Antimetabolites. Bull. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>98</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1263</first-page>
<last-page>1274</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lansiaux, A.: Antimetabolites. Bull. Cancer. 98(11), 1263–1274 (2011)</ref-fulltext>
<ce:source-text>Lansiaux, A.: Antimetabolites. Bull. Cancer. 98(11), 1263–1274 (2011)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Topoisomerase I inhibitors: Camptothecins and beyond</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Pommier</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>802</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pommier, Y.: Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer. 6(10), 789–802 (2006)</ref-fulltext>
<ce:source-text>Pommier, Y.: Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer. 6(10), 789–802 (2006)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Vinca alkaloids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Moudi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Prev. Med.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1231</first-page>
<last-page>1235</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moudi, M., et al.: Vinca alkaloids. Int. J. Prev. Med. 4(11), 1231–1235 (2013)</ref-fulltext>
<ce:source-text>Moudi, M., et al.: Vinca alkaloids. Int. J. Prev. Med. 4(11), 1231–1235 (2013)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Taxane pathway. Pharmacogenet</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Oshiro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Genomics</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>979</first-page>
<last-page>983</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Oshiro, C., et al.: Taxane pathway. Pharmacogenet. Genomics. 19(12), 979–983 (2009)</ref-fulltext>
<ce:source-text>Oshiro, C., et al.: Taxane pathway. Pharmacogenet. Genomics. 19(12), 979–983 (2009)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nurgali</ce:surname>
</author>
<author seq="2">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Abalo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018)</ref-fulltext>
<ce:source-text>Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Boltong</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Keast</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Aranda</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2765</first-page>
<last-page>2774</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Boltong, A., Keast, R., Aranda, S.: Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 20(11), 2765–2774 (2012)</ref-fulltext>
<ce:source-text>Boltong, A., Keast, R., Aranda, S.: Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 20(11), 2765–2774 (2012)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Drug-induced myelosuppression: Diagnosis and management</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.J.</ce:initials>
<ce:surname>Carey</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Drug Saf</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>691</first-page>
<last-page>706</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Carey, P.J.: Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691–706 (2003)</ref-fulltext>
<ce:source-text>Carey, P.J.: Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691–706 (2003)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.L.</ce:initials>
<ce:surname>Rapoport</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rapoport, B.L.: Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front. Pharmacol. 8, 19 (2017)</ref-fulltext>
<ce:source-text>Rapoport, B.L.: Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front. Pharmacol. 8, 19 (2017)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>The role of vagal neurocircuits in the regulation of nausea and vomiting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Babic</ce:surname>
</author>
<author seq="2">
<ce:initials>K.N.</ce:initials>
<ce:surname>Browning</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>722</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>38</first-page>
<last-page>47</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Babic, T., Browning, K.N.: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur. J. Pharmacol. 722, 38–47 (2014)</ref-fulltext>
<ce:source-text>Babic, T., Browning, K.N.: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur. J. Pharmacol. 722, 38–47 (2014)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>GDF15 Induces Anorexia through Nausea and Emesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Borner, T., et al.: GDF15 Induces Anorexia through Nausea and Emesis. Cell Metab. (2020)</ref-fulltext>
<ce:source-text>Borner, T., et al.: GDF15 Induces Anorexia through Nausea and Emesis. Cell Metab. (2020)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>The MIC-1/GDF15-GFRAL pathway in energy homeostasis: Implications for obesity, cachexia, and other associated diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.W.W.</ce:initials>
<ce:surname>Tsai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>353</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsai, V.W.W., et al.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28(3), 353–368 (2018)</ref-fulltext>
<ce:source-text>Tsai, V.W.W., et al.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28(3), 353–368 (2018)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Cinausero</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>354</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cinausero, M., et al.: New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017)</ref-fulltext>
<ce:source-text>Cinausero, M., et al.: New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment of oral mucositis due to chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Chaveli-Lopez</ce:surname>
</author>
<author seq="2">
<ce:initials>J.V.</ce:initials>
<ce:surname>Bagan-Sebastian</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Exp Dent</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e201</first-page>
<last-page>e209</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chaveli-Lopez, B., Bagan-Sebastian, J.V.: Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 8(2), e201–e209 (2016)</ref-fulltext>
<ce:source-text>Chaveli-Lopez, B., Bagan-Sebastian, J.V.: Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 8(2), e201–e209 (2016)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of chemotherapy-induced peripheral neuropathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Zajaczkowska</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zajaczkowska, R., et al.: Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20(6) (2019)</ref-fulltext>
<ce:source-text>Zajaczkowska, R., et al.: Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20(6) (2019)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Kolb</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JAMA Neurol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>73</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>860</first-page>
<last-page>866</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kolb, N.A., et al.: The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 73(7), 860–866 (2016)</ref-fulltext>
<ce:source-text>Kolb, N.A., et al.: The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 73(7), 860–866 (2016)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy, cognitive impairment and hippocampal toxicity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Dietrich</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Prust</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Kaiser</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neuroscience</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>309</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>224</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dietrich, J., Prust, M., Kaiser, J.: Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 309, 224–232 (2015)</ref-fulltext>
<ce:source-text>Dietrich, J., Prust, M., Kaiser, J.: Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 309, 224–232 (2015)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Caeyenberghs</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neurosci. Biobehav. Rev</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>92</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>304</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, M., Caeyenberghs, K.: Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018)</ref-fulltext>
<ce:source-text>Li, M., Caeyenberghs, K.: Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer- and chemotherapy-induced musculoskeletal degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JBMR Plus</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sturgeon, K.M., et al.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ref-fulltext>
<ce:source-text>Sturgeon, K.M., et al.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced osteoporosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Baylink</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="1983"/>
<volisspag>
<volume-issue-number>
<vol-first>309</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>306</first-page>
<last-page>308</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baylink, D.J.: Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309(5), 306–308 (1983)</ref-fulltext>
<ce:source-text>Baylink, D.J.: Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309(5), 306–308 (1983)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Quach</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>886</first-page>
<last-page>897</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Quach, J.M., et al.: Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J. Bone Miner. Res. 30(5), 886–897 (2015)</ref-fulltext>
<ce:source-text>Quach, J.M., et al.: Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J. Bone Miner. Res. 30(5), 886–897 (2015)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Saarto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1341</first-page>
<last-page>1347</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saarto, T., et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997)</ref-fulltext>
<ce:source-text>Saarto, T., et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Rapid Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Essex</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Essex, A.L., et al.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ref-fulltext>
<ce:source-text>Essex, A.L., et al.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Fatigue and quality of life outcomes of exercise during cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Mock</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Pract</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>119</first-page>
<last-page>127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mock, V., et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 9(3), 119–127 (2001)</ref-fulltext>
<ce:source-text>Mock, V., et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 9(3), 119–127 (2001)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ref-fulltext>
<ce:source-text>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>420</first-page>
<last-page>426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., Couch, M.E., Bonetto, A.: Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support. Palliat. Care. 12(4), 420–426 (2018)</ref-fulltext>
<ce:source-text>Pin, F., Couch, M.E., Bonetto, A.: Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support. Palliat. Care. 12(4), 420–426 (2018)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Le Bricon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Metabolism</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1340</first-page>
<last-page>1348</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Le Bricon, T., et al.: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44(10), 1340–1348 (1995)</ref-fulltext>
<ce:source-text>Le Bricon, T., et al.: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44(10), 1340–1348 (1995)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Crawford</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>68</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Crawford, S.: Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68 (2013)</ref-fulltext>
<ce:source-text>Crawford, S.: Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68 (2013)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2012</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Naishadham</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)</ref-fulltext>
<ce:source-text>Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Thoresen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>65</first-page>
<last-page>72</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thoresen, L., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin. Nutr. 32(1), 65–72 (2013)</ref-fulltext>
<ce:source-text>Thoresen, L., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin. Nutr. 32(1), 65–72 (2013)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43442</first-page>
<last-page>43460</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huot, J.R., et al.: Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel). 11(4) (2019)</ref-fulltext>
<ce:source-text>Huot, J.R., et al.: Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel). 11(4) (2019)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>140</first-page>
<last-page>154</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. 10(1), 140–154 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. 10(1), 140–154 (2019)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Naito</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>571</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Naito, T., et al.: Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 17(1), 571 (2017)</ref-fulltext>
<ce:source-text>Naito, T., et al.: Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 17(1), 571 (2017)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic value of the six-minute walk in advanced non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Kasymjanova</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Thorac. Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>602</first-page>
<last-page>607</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kasymjanova, G., et al.: Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J. Thorac. Oncol. 4(5), 602–607 (2009)</ref-fulltext>
<ce:source-text>Kasymjanova, G., et al.: Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J. Thorac. Oncol. 4(5), 602–607 (2009)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Kurk</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>909</first-page>
<last-page>919</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kurk, S.A., et al.: Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J. Cachexia. Sarcopenia Muscle. 9(5), 909–919 (2018)</ref-fulltext>
<ce:source-text>Kurk, S.A., et al.: Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J. Cachexia. Sarcopenia Muscle. 9(5), 909–919 (2018)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle strength in breast cancer patients receiving different treatment regimes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>305</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ref-fulltext>
<ce:source-text>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Freedman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2248</first-page>
<last-page>2253</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Freedman, R.J., et al.: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J. Clin. Endocrinol. Metab. 89(5), 2248–2253 (2004)</ref-fulltext>
<ce:source-text>Freedman, R.J., et al.: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J. Clin. Endocrinol. Metab. 89(5), 2248–2253 (2004)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Awad</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>74</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Awad, S., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31(1), 74–77 (2012)</ref-fulltext>
<ce:source-text>Awad, S., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31(1), 74–77 (2012)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Poterucha</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Burnette</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med. Oncol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1005</first-page>
<last-page>1009</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Poterucha, T., Burnette, B., Jatoi, A.: A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 29(2), 1005–1009 (2012)</ref-fulltext>
<ce:source-text>Poterucha, T., Burnette, B., Jatoi, A.: A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 29(2), 1005–1009 (2012)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cisplatin-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Toxicol. Appl. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>278</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>190</first-page>
<last-page>199</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Stacchiotti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>2014</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Stacchiotti, A., et al.: Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study. Oxidative Med. Cell. Longev. 2014, 840951 (2014)</ref-fulltext>
<ce:source-text>Stacchiotti, A., et al.: Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study. Oxidative Med. Cell. Longev. 2014, 840951 (2014)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Feather</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>650</first-page>
<last-page>658</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Feather, C.E., et al.: Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle Nerve. 57(4), 650–658 (2018)</ref-fulltext>
<ce:source-text>Feather, C.E., et al.: Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle Nerve. 57(4), 650–658 (2018)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.C.</ce:initials>
<ce:surname>Sorensen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>137</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sorensen, J.C., et al.: BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017)</ref-fulltext>
<ce:source-text>Sorensen, J.C., et al.: BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. (2019)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.A.</ce:initials>
<ce:surname>de Lima</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>233</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9652</first-page>
<last-page>9662</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>de Lima, E.A., et al.: Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J. Cell. Physiol. 233(12), 9652–9662 (2018)</ref-fulltext>
<ce:source-text>de Lima, E.A., et al.: Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J. Cell. Physiol. 233(12), 9652–9662 (2018)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Hulmi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>417</first-page>
<last-page>432</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hulmi, J.J., et al.: Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle. 9(2), 417–432 (2018)</ref-fulltext>
<ce:source-text>Hulmi, J.J., et al.: Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle. 9(2), 417–432 (2018)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Nissinen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Nissinen, T.A., et al.: Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016)</ref-fulltext>
<ce:source-text>Nissinen, T.A., et al.: Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Powers</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pflugers Arch</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>471</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Powers, S.K., et al.: Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch. 471(3), 441–453 (2019)</ref-fulltext>
<ce:source-text>Powers, S.K., et al.: Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch. 471(3), 441–453 (2019)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nishiyama</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3723</first-page>
<last-page>3738</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nishiyama, K., et al.: Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br. J. Pharmacol. 176(18), 3723–3738 (2019)</ref-fulltext>
<ce:source-text>Nishiyama, K., et al.: Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br. J. Pharmacol. 176(18), 3723–3738 (2019)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.D.</ce:initials>
<ce:surname>Dewys</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Med</ref-sourcetitle>
<ref-publicationyear first="1980"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dewys, W.D., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ref-fulltext>
<ce:source-text>Dewys, W.D., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Grothey</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>381</vol-first>
<iss-first>9863</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>303</first-page>
<last-page>312</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Grothey, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863), 303–312 (2013)</ref-fulltext>
<ce:source-text>Grothey, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863), 303–312 (2013)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Shingina</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Can. J. Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>393</first-page>
<last-page>396</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shingina, A., et al.: In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can. J. Gastroenterol. 27(7), 393–396 (2013)</ref-fulltext>
<ce:source-text>Shingina, A., et al.: In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can. J. Gastroenterol. 27(7), 393–396 (2013)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Sirago</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sirago, G., et al.: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7(1), 13017 (2017)</ref-fulltext>
<ce:source-text>Sirago, G., et al.: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7(1), 13017 (2017)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Tarpey</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19709</first-page>
<last-page>19722</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tarpey, M.D., et al.: Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J. Biol. Chem. 294(51), 19709–19722 (2019)</ref-fulltext>
<ce:source-text>Tarpey, M.D., et al.: Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J. Biol. Chem. 294(51), 19709–19722 (2019)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle weakness and neuromuscular junctions in aging and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Shigemoto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Geriatr Gerontol Int</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>S137</first-page>
<last-page>S147</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shigemoto, K., et al.: Muscle weakness and neuromuscular junctions in aging and disease. Geriatr Gerontol Int. 10(Suppl 1), S137–S147 (2010)</ref-fulltext>
<ce:source-text>Shigemoto, K., et al.: Muscle weakness and neuromuscular junctions in aging and disease. Geriatr Gerontol Int. 10(Suppl 1), S137–S147 (2010)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.J.</ce:initials>
<ce:surname>de Vos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Genet</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2720</first-page>
<last-page>2728</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>De Vos, K.J., et al.: Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16(22), 2720–2728 (2007)</ref-fulltext>
<ce:source-text>De Vos, K.J., et al.: Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16(22), 2720–2728 (2007)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Magrane</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurosci</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>229</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Magrane, J., et al.: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32(1), 229–242 (2012)</ref-fulltext>
<ce:source-text>Magrane, J., et al.: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32(1), 229–242 (2012)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular disease: Mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Malkki</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Neurol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>556</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Malkki, H.: Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat. Rev. Neurol. 12(10), 556 (2016)</ref-fulltext>
<ce:source-text>Malkki, H.: Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat. Rev. Neurol. 12(10), 556 (2016)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ahn</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>428</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ahn, B., et al.: Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. J. Cachexia. Sarcopenia Muscle. 10(2), 411–428 (2019)</ref-fulltext>
<ce:source-text>Ahn, B., et al.: Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. J. Cachexia. Sarcopenia Muscle. 10(2), 411–428 (2019)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Rudolf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Age (Dordr.).</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1663</first-page>
<last-page>1674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rudolf, R., et al.: Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways. Age (Dordr.). 35(5), 1663–1674 (2013)</ref-fulltext>
<ce:source-text>Rudolf, R., et al.: Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways. Age (Dordr.). 35(5), 1663–1674 (2013)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.T.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Integr. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wu, C.T., et al.: D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway. Integr. Cancer Ther. 18, 1534735419828832 (2019)</ref-fulltext>
<ce:source-text>Wu, C.T., et al.: D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway. Integr. Cancer Ther. 18, 1534735419828832 (2019)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>McQuade</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3502</first-page>
<last-page>3521</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McQuade, R.M., et al.: Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173(24), 3502–3521 (2016)</ref-fulltext>
<ce:source-text>McQuade, R.M., et al.: Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173(24), 3502–3521 (2016)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.G.</ce:initials>
<ce:surname>Webster</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>146</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1027</first-page>
<last-page>1039</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webster, R.G., et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005)</ref-fulltext>
<ce:source-text>Webster, R.G., et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Modification of neuromuscular junction protein expression by exercise and doxorubicin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Huertas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Huertas, A.M., et al.: Modification of neuromuscular junction protein expression by exercise and doxorubicin. Med. Sci. Sports Exerc. (2020)</ref-fulltext>
<ce:source-text>Huertas, A.M., et al.: Modification of neuromuscular junction protein expression by exercise and doxorubicin. Med. Sci. Sports Exerc. (2020)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular junctions are stable in patients with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Boehm</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Boehm, I., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ref-fulltext>
<ce:source-text>Boehm, I., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., et al.: Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 5(10), e13604 (2010)</ref-fulltext>
<ce:source-text>Penna, F., et al.: Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 5(10), e13604 (2010)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>p38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Stress</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>311</first-page>
<last-page>324</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, Z., et al.: P38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice. Cell Stress. 2(11), 311–324 (2018)</ref-fulltext>
<ce:source-text>Liu, Z., et al.: P38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice. Cell Stress. 2(11), 311–324 (2018)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Quan-Jun</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>334</first-page>
<last-page>343</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Quan-Jun, Y., et al.: Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol. Cancer Ther. 16(2), 334–343 (2017)</ref-fulltext>
<ce:source-text>Quan-Jun, Y., et al.: Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol. Cancer Ther. 16(2), 334–343 (2017)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>132</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.A., et al.: Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved. J. Cachexia. Sarcopenia Muscle. 6(2), 132–143 (2015)</ref-fulltext>
<ce:source-text>Chen, J.A., et al.: Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved. J. Cachexia. Sarcopenia Muscle. 6(2), 132–143 (2015)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Dexamethasone exacerbates cisplatin-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Pharmacol. Physiol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp. Pharmacol. Physiol. 46(1), 19–28 (2019)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp. Pharmacol. Physiol. 46(1), 19–28 (2019)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Magga</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Ther</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>600</first-page>
<last-page>610</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Magga, J., et al.: Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury. Mol. Ther. 27(3), 600–610 (2019)</ref-fulltext>
<ce:source-text>Magga, J., et al.: Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury. Mol. Ther. 27(3), 600–610 (2019)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Mitry</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Mitry, M.A., et al.: Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am. J. Physiol. Cell Physiol. (2020)</ref-fulltext>
<ce:source-text>Mitry, M.A., et al.: Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am. J. Physiol. Cell Physiol. (2020)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Yu, X., et al.: Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem. Biophys. Res. Commun. (2019)</ref-fulltext>
<ce:source-text>Yu, X., et al.: Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem. Biophys. Res. Commun. (2019)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.F.</ce:initials>
<ce:surname>Cheng</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Apoptosis</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>894</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, C.F., et al.: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis. 13(7), 883–894 (2008)</ref-fulltext>
<ce:source-text>Cheng, C.F., et al.: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis. 13(7), 883–894 (2008)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of rutin on cisplatin-induced oxidative cardiac damage in rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Topal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Anatol. J. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>136</first-page>
<last-page>142</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Topal, I., et al.: The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol. J. Cardiol. 20(3), 136–142 (2018)</ref-fulltext>
<ce:source-text>Topal, I., et al.: The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol. J. Cardiol. 20(3), 136–142 (2018)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Understanding the molecular basis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>762</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Constantinou</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
<last-page>24</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Constantinou, C., et al.: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27(1), 15–24 (2011)</ref-fulltext>
<ce:source-text>Constantinou, C., et al.: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27(1), 15–24 (2011)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>On the origin of cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Warburg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1956"/>
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>3191</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>309</first-page>
<last-page>314</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Warburg, O.: On the origin of cancer cells. Science. 123(3191), 309–314 (1956)</ref-fulltext>
<ce:source-text>Warburg, O.: On the origin of cancer cells. Science. 123(3191), 309–314 (1956)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Warburg effect: The metabolic requirements of cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
</author>
<author seq="2">
<ce:initials>L.C.</ce:initials>
<ce:surname>Cantley</ce:surname>
</author>
<author seq="3">
<ce:initials>C.B.</ce:initials>
<ce:surname>Thompson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>324</vol-first>
<iss-first>5930</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1029</first-page>
<last-page>1033</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324(5930), 1029–1033 (2009)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324(5930), 1029–1033 (2009)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Energy metabolism in cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Rohm</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>EMBO Rep</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rohm, M., et al.: Energy metabolism in cachexia. EMBO Rep. 20, 4 (2019)</ref-fulltext>
<ce:source-text>Rohm, M., et al.: Energy metabolism in cachexia. EMBO Rep. 20, 4 (2019)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>279</first-page>
<last-page>286</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>163</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>643</first-page>
<last-page>655</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kazak, L., et al.: A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell. 163(3), 643–655 (2015)</ref-fulltext>
<ce:source-text>Kazak, L., et al.: A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell. 163(3), 643–655 (2015)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Lipid metabolism in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.D.</ce:initials>
<ce:surname>Mulligan</ce:surname>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Beck</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>66</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>57</first-page>
<last-page>61</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mulligan, H.D., Beck, S.A., Tisdale, M.J.: Lipid metabolism in cancer cachexia. Br. J. Cancer. 66(1), 57–61 (1992)</ref-fulltext>
<ce:source-text>Mulligan, H.D., Beck, S.A., Tisdale, M.J.: Lipid metabolism in cancer cachexia. Br. J. Cancer. 66(1), 57–61 (1992)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin resistance and body composition in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Dev</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Dalal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>ii18</first-page>
<last-page>ii26</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dev, R., Bruera, E., Dalal, S.: Insulin resistance and body composition in cancer patients. Ann. Oncol. 29(suppl_2), ii18–ii26 (2018)</ref-fulltext>
<ce:source-text>Dev, R., Bruera, E., Dalal, S.: Insulin resistance and body composition in cancer patients. Ann. Oncol. 29(suppl_2), ii18–ii26 (2018)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Hyperglycemia and insulin resistance: Possible mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Tomas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. N. Y. Acad. Sci</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>967</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43</first-page>
<last-page>51</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tomas, E., et al.: Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 967, 43–51 (2002)</ref-fulltext>
<ce:source-text>Tomas, E., et al.: Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 967, 43–51 (2002)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Acute hyperglycemia associated with anti-cancer medication</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Hwangbo</ce:surname>
</author>
<author seq="2">
<ce:initials>E.K.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinol. Metab. (Seoul).</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>23</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hwangbo, Y., Lee, E.K.: Acute hyperglycemia associated with anti-cancer medication. Endocrinol. Metab. (Seoul). 32(1), 23–29 (2017)</ref-fulltext>
<ce:source-text>Hwangbo, Y., Lee, E.K.: Acute hyperglycemia associated with anti-cancer medication. Endocrinol. Metab. (Seoul). 32(1), 23–29 (2017)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Pathophysiology of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Younes</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Noguchi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Hosp. Clin. Fac. Med. Sao Paulo</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>181</first-page>
<last-page>193</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Younes, R.N., Noguchi, Y.: Pathophysiology of cancer cachexia. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 55(5), 181–193 (2000)</ref-fulltext>
<ce:source-text>Younes, R.N., Noguchi, Y.: Pathophysiology of cancer cachexia. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 55(5), 181–193 (2000)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.M.</ce:initials>
<ce:surname>Cho</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Pediatr. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>226</first-page>
<last-page>228</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cho, E.M., et al.: Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia. Ann. Pediatr. Endocrinol. Metab. 23(4), 226–228 (2018)</ref-fulltext>
<ce:source-text>Cho, E.M., et al.: Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia. Ann. Pediatr. Endocrinol. Metab. 23(4), 226–228 (2018)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of the activity of the pyruvate dehydrogenase complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Harris</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Enzym. Regul</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>249</first-page>
<last-page>259</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harris, R.A., et al.: Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249–259 (2002)</ref-fulltext>
<ce:source-text>Harris, R.A., et al.: Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249–259 (2002)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7778</first-page>
<last-page>7790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33(6), 7778–7790 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33(6), 7778–7790 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>41</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43202</first-page>
<last-page>43215</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget. 6(41), 43202–43215 (2015)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget. 6(41), 43202–43215 (2015)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Shum</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Aging (Albany NY)</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>133</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shum, A.M., et al.: Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY). 4(2), 133–143 (2012)</ref-fulltext>
<ce:source-text>Shum, A.M., et al.: Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY). 4(2), 133–143 (2012)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle atrophy and dysfunction in breast cancer patients: Role for chemotherapy-derived oxidant stress</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Guigni</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>315</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>C744</first-page>
<last-page>C756</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guigni, B.A., et al.: Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am. J. Physiol. Cell Physiol. 315(5), C744–C756 (2018)</ref-fulltext>
<ce:source-text>Guigni, B.A., et al.: Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am. J. Physiol. Cell Physiol. 315(5), C744–C756 (2018)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms for fiber-type specificity of skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Pessin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>243</first-page>
<last-page>250</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, Y., Pessin, J.E.: Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care. 16(3), 243–250 (2013)</ref-fulltext>
<ce:source-text>Wang, Y., Pessin, J.E.: Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care. 16(3), 243–250 (2013)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Role of oxidative stress as key regulator of muscle wasting during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Abrigo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>2018</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Abrigo, J., et al.: Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxidative Med. Cell. Longev. 2018, 2063179 (2018)</ref-fulltext>
<ce:source-text>Abrigo, J., et al.: Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxidative Med. Cell. Longev. 2018, 2063179 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.L.</ce:initials>
<ce:surname>Eley</ce:surname>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>282</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7087</first-page>
<last-page>7097</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Eley, H.L., Tisdale, M.J.: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282(10), 7087–7097 (2007)</ref-fulltext>
<ce:source-text>Eley, H.L., Tisdale, M.J.: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282(10), 7087–7097 (2007)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.I.</ce:initials>
<ce:surname>Block</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1227</first-page>
<last-page>1239</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Block, K.I., et al.: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227–1239 (2008)</ref-fulltext>
<ce:source-text>Block, K.I., et al.: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227–1239 (2008)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cannavino</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>592</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4575</first-page>
<last-page>4589</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cannavino, J., et al.: PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592(20), 4575–4589 (2014)</ref-fulltext>
<ce:source-text>Cannavino, J., et al.: PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592(20), 4575–4589 (2014)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>44</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>16260</first-page>
<last-page>16265</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sandri, M., et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. 103(44), 16260–16265 (2006)</ref-fulltext>
<ce:source-text>Sandri, M., et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. 103(44), 16260–16265 (2006)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., et al.: Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One. 7(3), e33426 (2012)</ref-fulltext>
<ce:source-text>Wang, X., et al.: Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One. 7(3), e33426 (2012)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.L.</ce:initials>
<ce:surname>Xi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Lett</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4013</first-page>
<last-page>4020</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xi, Q.L., et al.: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol. Lett. 12(5), 4013–4020 (2016)</ref-fulltext>
<ce:source-text>Xi, Q.L., et al.: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol. Lett. 12(5), 4013–4020 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Molinari</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>954</first-page>
<last-page>973</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Molinari, F., et al.: The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J. Cachexia. Sarcopenia Muscle. 8(6), 954–973 (2017)</ref-fulltext>
<ce:source-text>Molinari, F., et al.: The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J. Cachexia. Sarcopenia Muscle. 8(6), 954–973 (2017)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Ballaro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Ballaro, R., et al.: Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis. Cancers (Basel). 11(3) (2019)</ref-fulltext>
<ce:source-text>Ballaro, R., et al.: Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis. Cancers (Basel). 11(3) (2019)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.S.</ce:initials>
<ce:surname>Padilha</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Appl. Physiol. Nutr. Metab</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>916</first-page>
<last-page>923</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Padilha, C.S., et al.: Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl. Physiol. Nutr. Metab. 42(9), 916–923 (2017)</ref-fulltext>
<ce:source-text>Padilha, C.S., et al.: Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl. Physiol. Nutr. Metab. 42(9), 916–923 (2017)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Combined exercise training positively affects muscle wasting in tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ranjbar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1387</first-page>
<last-page>1395</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ranjbar, K., et al.: Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med. Sci. Sports Exerc. 51(7), 1387–1395 (2019)</ref-fulltext>
<ce:source-text>Ranjbar, K., et al.: Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med. Sci. Sports Exerc. 51(7), 1387–1395 (2019)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Ballaro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5482</first-page>
<last-page>5494</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ballaro, R., et al.: Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33(4), 5482–5494 (2019)</ref-fulltext>
<ce:source-text>Ballaro, R., et al.: Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33(4), 5482–5494 (2019)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pflugers Arch</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>469</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1495</first-page>
<last-page>1505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 469(11), 1495–1505 (2017)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 469(11), 1495–1505 (2017)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cave</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3337</first-page>
<last-page>3351</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cave, J., et al.: A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 26(10), 3337–3351 (2018)</ref-fulltext>
<ce:source-text>Cave, J., et al.: A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 26(10), 3337–3351 (2018)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Mijwel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res. Treat</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>169</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>93</first-page>
<last-page>103</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mijwel, S., et al.: Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial. Breast Cancer Res. Treat. 169(1), 93–103 (2018)</ref-fulltext>
<ce:source-text>Mijwel, S., et al.: Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial. Breast Cancer Res. Treat. 169(1), 93–103 (2018)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of muscle growth by multiple ligands signaling through activin type II receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>50</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18117</first-page>
<last-page>18122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, S.J., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ref-fulltext>
<ce:source-text>Lee, S.J., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Activin signaling as an emerging target for therapeutic interventions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Tsuchida</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Commun. Signal</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsuchida, K., et al.: Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15 (2009)</ref-fulltext>
<ce:source-text>Tsuchida, K., et al.: Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15 (2009)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Skelet. Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>26</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hatakeyama, S., et al.: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle. 6, 26 (2016)</ref-fulltext>
<ce:source-text>Hatakeyama, S., et al.: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle. 6, 26 (2016)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Nissinen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>514</first-page>
<last-page>529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nissinen, T.A., et al.: Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia. Sarcopenia Muscle. 9(3), 514–529 (2018)</ref-fulltext>
<ce:source-text>Nissinen, T.A., et al.: Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia. Sarcopenia Muscle. 9(3), 514–529 (2018)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>The systemic activin response to pancreatic cancer: Implications for effective cancer cachexia therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhong</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1083</first-page>
<last-page>1101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhong, X., et al.: The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle. 10(5), 1083–1101 (2019)</ref-fulltext>
<ce:source-text>Zhong, X., et al.: The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle. 10(5), 1083–1101 (2019)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>142</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>531</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, X., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ref-fulltext>
<ce:source-text>Zhou, X., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Bone and muscle: Interactions beyond mechanical</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Brotto</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Bonewald</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>109</first-page>
<last-page>114</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brotto, M., Bonewald, L.: Bone and muscle: Interactions beyond mechanical. Bone. 80, 109–114 (2015)</ref-fulltext>
<ce:source-text>Brotto, M., Bonewald, L.: Bone and muscle: Interactions beyond mechanical. Bone. 80, 109–114 (2015)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Differential bone loss in mouse models of colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>679</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>700</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Pamidronate attenuates muscle loss after pediatric burn injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Borsheim</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1369</first-page>
<last-page>1372</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borsheim, E., et al.: Pamidronate attenuates muscle loss after pediatric burn injury. J. Bone Miner. Res. 29(6), 1369–1372 (2014)</ref-fulltext>
<ce:source-text>Borsheim, E., et al.: Pamidronate attenuates muscle loss after pediatric burn injury. J. Bone Miner. Res. 29(6), 1369–1372 (2014)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>543</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front. Endocrinol. (Lausanne). 10, 543 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front. Endocrinol. (Lausanne). 10, 543 (2019)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bonnet</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>129</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3214</first-page>
<last-page>3223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonnet, N., et al.: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129(8), 3214–3223 (2019)</ref-fulltext>
<ce:source-text>Bonnet, N., et al.: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129(8), 3214–3223 (2019)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Nutrition interventions to treat low muscle mass in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Prado</ce:surname>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Purcell</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Laviano</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Prado, C.M., Purcell, S.A., Laviano, A.: Nutrition interventions to treat low muscle mass in cancer. J. Cachexia. Sarcopenia Muscle. (2020)</ref-fulltext>
<ce:source-text>Prado, C.M., Purcell, S.A., Laviano, A.: Nutrition interventions to treat low muscle mass in cancer. J. Cachexia. Sarcopenia Muscle. (2020)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Alterations of protein turnover underlying disuse atrophy in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.M.</ce:initials>
<ce:surname>Phillips</ce:surname>
</author>
<author seq="2">
<ce:initials>E.I.</ce:initials>
<ce:surname>Glover</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Rennie</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2009.</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>645</first-page>
<last-page>654</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Phillips, S.M., Glover, E.I., Rennie, M.J.: Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. J. Appl. Physiol. 2009. 107(3), 645–654 (1985)</ref-fulltext>
<ce:source-text>Phillips, S.M., Glover, E.I., Rennie, M.J.: Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. J. Appl. Physiol. 2009. 107(3), 645–654 (1985)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.S.</ce:initials>
<ce:surname>Van der Meij</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2399</first-page>
<last-page>2407</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van der Meij, B.S., et al.: Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin. Nutr. 38(5), 2399–2407 (2019)</ref-fulltext>
<ce:source-text>van der Meij, B.S., et al.: Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin. Nutr. 38(5), 2399–2407 (2019)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>ESPEN guidelines on nutrition in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11</first-page>
<last-page>48</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arends, J., et al.: ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36(1), 11–48 (2017)</ref-fulltext>
<ce:source-text>Arends, J., et al.: ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36(1), 11–48 (2017)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Cereda</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>16</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6923</first-page>
<last-page>6932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cereda, E., et al.: Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Med. 8(16), 6923–6932 (2019)</ref-fulltext>
<ce:source-text>Cereda, E., et al.: Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Med. 8(16), 6923–6932 (2019)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bumrungpert</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Med. Food</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>612</first-page>
<last-page>616</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bumrungpert, A., et al.: Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial. J. Med. Food. 21(6), 612–616 (2018)</ref-fulltext>
<ce:source-text>Bumrungpert, A., et al.: Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial. J. Med. Food. 21(6), 612–616 (2018)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.G.</ce:initials>
<ce:surname>Tozer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Antioxid. Redox Signal</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>395</first-page>
<last-page>402</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tozer, R.G., et al.: Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox Signal. 10(2), 395–402 (2008)</ref-fulltext>
<ce:source-text>Tozer, R.G., et al.: Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox Signal. 10(2), 395–402 (2008)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Cruz</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Oliveira</ce:surname>
</author>
<author seq="3">
<ce:initials>M.C.C.</ce:initials>
<ce:surname>Gomes-Marcondes</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>96</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>253</first-page>
<last-page>260</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cruz, B., Oliveira, A., Gomes-Marcondes, M.C.C.: L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 96, 253–260 (2017)</ref-fulltext>
<ce:source-text>Cruz, B., Oliveira, A., Gomes-Marcondes, M.C.C.: L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 96, 253–260 (2017)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Toneto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>577</first-page>
<last-page>586</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Toneto, A.T., et al.: Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia. Sarcopenia Muscle. 7(5), 577–586 (2016)</ref-fulltext>
<ce:source-text>Toneto, A.T., et al.: Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia. Sarcopenia Muscle. 7(5), 577–586 (2016)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>713</first-page>
<last-page>720</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aversa, Z., et al.: beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38(3), 713–720 (2011)</ref-fulltext>
<ce:source-text>Aversa, Z., et al.: beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38(3), 713–720 (2011)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>May</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Surg</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>183</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>471</first-page>
<last-page>479</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>May, P.E., et al.: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183(4), 471–479 (2002)</ref-fulltext>
<ce:source-text>May, P.E., et al.: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183(4), 471–479 (2002)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Gramignano</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nutrition</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>136</first-page>
<last-page>145</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gramignano, G., et al.: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22(2), 136–145 (2006)</ref-fulltext>
<ce:source-text>Gramignano, G., et al.: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22(2), 136–145 (2006)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1775</first-page>
<last-page>1782</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murphy, R.A., et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 117(8), 1775–1782 (2011)</ref-fulltext>
<ce:source-text>Murphy, R.A., et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 117(8), 1775–1782 (2011)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>311</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>R89</first-page>
<last-page>R96</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borner, T., et al.: The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311(1), R89–R96 (2016)</ref-fulltext>
<ce:source-text>Borner, T., et al.: The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311(1), R89–R96 (2016)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Fujitsuka</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Transl. Psychiatry</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Fujitsuka, N., et al.: Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry. 1, e23 (2011)</ref-fulltext>
<ce:source-text>Fujitsuka, N., et al.: Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry. 1, e23 (2011)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.O.</ce:initials>
<ce:surname>Villars</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Villars, F.O., et al.: Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors. Int. J. Mol. Sci. 18(5) (2017)</ref-fulltext>
<ce:source-text>Villars, F.O., et al.: Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors. Int. J. Mol. Sci. 18(5) (2017)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Yoshimura</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>811</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>37</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshimura, M., et al.: Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur. J. Pharmacol. 811, 30–37 (2017)</ref-fulltext>
<ce:source-text>Yoshimura, M., et al.: Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur. J. Pharmacol. 811, 30–37 (2017)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shiomi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>818</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>148</first-page>
<last-page>157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shiomi, Y., et al.: Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur. J. Pharmacol. 818, 148–157 (2018)</ref-fulltext>
<ce:source-text>Shiomi, Y., et al.: Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur. J. Pharmacol. 818, 148–157 (2018)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Hiura</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4785</first-page>
<last-page>4794</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hiura, Y., et al.: Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer. 118(19), 4785–4794 (2012)</ref-fulltext>
<ce:source-text>Hiura, Y., et al.: Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer. 118(19), 4785–4794 (2012)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_10</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">New Developments in Targeting Cancer Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>Janice</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.I.</ce:initials>
<ce:surname>Ramage</ce:surname>
<ce:given-name>Michael I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>Richard J. E.</ce:given-name>
<ce:e-address>richard.skipworth@nhslothian.scot.nhs.uk</ce:e-address>
</author>
<affiliation>
<organization>Royal Infirmary of Edinburgh</organization>
<city>Edinburgh</city>
<country iso-code="GBR"/>
<ce:source-text>Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>Richard J. E.</ce:given-name>
</person>
<affiliation>
<organization>Royal Infirmary of Edinburgh</organization>
<city>Edinburgh</city>
<country iso-code="GBR"/>
<ce:source-text>Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK</ce:source-text>
</affiliation>
<ce:e-address>richard.skipworth@nhslothian.scot.nhs.uk</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Within the cancer population, 50–80% of patients will develop cachexia, impacting negatively on their ability to tolerate or gain benefit from either curative or palliative treatment. To date, although collaborative management guidelines have been developed, there are no internationally standardised management programmes used in the clinical forum for patients with cancer cachexia. Furthermore, current available treatment strategies have limited efficacy. This chapter considers recent developments in the ability to target cachexia. Such “targeting” comes in two key forms: firstly, the ability to target and recognise new patients with, or at risk of, developing cancer cachexia. Some of the new developments in this field of study relate not just to improvements in patient targeting, but also a better understanding of the inherent pitfalls in this process. The second aspect of targeting relates to the identification of novel therapeutic biological targets for further clinical investigation.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>171</first-page>
<last-page>192</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="125">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.D.</ce:initials>
<ce:surname>Dewys</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Begg</ce:surname>
</author>
<author seq="3">
<ce:initials>P.T.</ce:initials>
<ce:surname>Lavin</ce:surname>
</author>
<author seq="4">
<ce:initials>P.R.</ce:initials>
<ce:surname>Band</ce:surname>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bennett</ce:surname>
</author>
<author seq="6">
<ce:initials>J.R.</ce:initials>
<ce:surname>Bertino</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Med</ref-sourcetitle>
<ref-publicationyear first="1980"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dewys, W.D., Begg, C., Lavin, P.T., Band, P.R., Bennett, J.M., Bertino, J.R., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ref-fulltext>
<ce:source-text>Dewys, W.D., Begg, C., Lavin, P.T., Band, P.R., Bennett, J.M., Bertino, J.R., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Diagnostic criteria of cancer cachexia: Relation to quality of life, exercise capacity and survival in unselected palliative care patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Wallengren</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Lundholm</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1569</first-page>
<last-page>1577</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wallengren, O., Lundholm, K., Bosaeus, I.: Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 21(6), 1569–1577 (2013)</ref-fulltext>
<ce:source-text>Wallengren, O., Lundholm, K., Bosaeus, I.: Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 21(6), 1569–1577 (2013)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: Prevalence and impact in medicine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
</author>
<author seq="2">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>400</first-page>
<last-page>407</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tan, B.H., Fearon, K.C.: Cachexia: Prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care. 11(4), 400–407 (2008)</ref-fulltext>
<ce:source-text>Tan, B.H., Fearon, K.C.: Cachexia: Prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care. 11(4), 400–407 (2008)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Strasser</ce:surname>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
</author>
<author seq="6">
<ce:initials>R.L.</ce:initials>
<ce:surname>Fainsinger</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Vagnildhaug</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Balstad</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Almberg</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Bruneli</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Knudsen</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Kaasa</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1871</first-page>
<last-page>1880</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vagnildhaug, O., Balstad, T., Almberg, S., Bruneli, C., Knudsen, A., Kaasa, S., et al.: A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Support Care Cancer. 26(6), 1871–1880 (2017)</ref-fulltext>
<ce:source-text>Vagnildhaug, O., Balstad, T., Almberg, S., Bruneli, C., Knudsen, A., Kaasa, S., et al.: A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Support Care Cancer. 26(6), 1871–1880 (2017)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Leblanc</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Nipp</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Rushing</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Samsa</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Locke</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kamal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>680</first-page>
<last-page>689</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>LeBlanc, T., Nipp, R., Rushing, C., Samsa, G., Locke, S., Kamal, A., et al.: Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J. Pain Symptom Manag. 49(4), 680–689 (2014)</ref-fulltext>
<ce:source-text>LeBlanc, T., Nipp, R., Rushing, C., Samsa, G., Locke, S., Kamal, A., et al.: Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J. Pain Symptom Manag. 49(4), 680–689 (2014)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Blum</ce:surname>
</author>
<author seq="2">
<ce:initials>G.B.</ce:initials>
<ce:surname>Stene</ce:surname>
</author>
<author seq="3">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Fayers</ce:surname>
</author>
<author seq="5">
<ce:initials>M.J.</ce:initials>
<ce:surname>Hjermstad</ce:surname>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1635</first-page>
<last-page>1642</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Blum, D., Stene, G.B., Solheim, T.S., Fayers, P., Hjermstad, M.J., Baracos, V.E., et al.: Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25(8), 1635–1642 (2014)</ref-fulltext>
<ce:source-text>Blum, D., Stene, G.B., Solheim, T.S., Fayers, P., Hjermstad, M.J., Baracos, V.E., et al.: Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25(8), 1635–1642 (2014)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia in cancer: What is in the definition?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Vanhoutte</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Van de Wiel</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Wouters</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Sels</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Bartolomeeussen</ce:surname>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Keersmaecker</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMJ Open Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., Keersmaecker, S.D., et al.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3(1), e000097 (2016)</ref-fulltext>
<ce:source-text>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., Keersmaecker, S.D., et al.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3(1), e000097 (2016)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A new definition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Argilés</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Bales</ce:surname>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Guttridge</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>793</first-page>
<last-page>799</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Morley, J.E., Argilés, J., Bales, C., Baracos, V., Guttridge, D., et al.: Cachexia: A new definition. Clin. Nutr. 27(6), 793–799 (2008)</ref-fulltext>
<ce:source-text>Evans, W.J., Morley, J.E., Argilés, J., Bales, C., Baracos, V., Guttridge, D., et al.: Cachexia: A new definition. Clin. Nutr. 27(6), 793–799 (2008)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mourtzakis</ce:surname>
</author>
<author seq="2">
<ce:initials>C.M.M.</ce:initials>
<ce:surname>Prado</ce:surname>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Lieffers</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Reiman</ce:surname>
</author>
<author seq="5">
<ce:initials>L.J.</ce:initials>
<ce:surname>McCargar</ce:surname>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Appl. Physiol. Nutr. Metab</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>997</first-page>
<last-page>1006</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006 (2008)</ref-fulltext>
<ce:source-text>Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006 (2008)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Birdsell</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Reiman</ce:surname>
</author>
<author seq="5">
<ce:initials>M.T.</ce:initials>
<ce:surname>Clandinin</ce:surname>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>McCargar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1539</first-page>
<last-page>1547</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al.: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547 (2013)</ref-fulltext>
<ce:source-text>Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al.: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547 (2013)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="2">
<ce:initials>M.F.</ce:initials>
<ce:surname>von Meyenfeldt</ce:surname>
</author>
<author seq="3">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>van Geenen</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Roy</ce:surname>
</author>
<author seq="6">
<ce:initials>D.J.</ce:initials>
<ce:surname>Gouma</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Gut</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1479</first-page>
<last-page>1486</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K.C.H., Von Meyenfeldt, M.F., Moses, A.G.W., Van Geenen, R., Roy, A., Gouma, D.J., et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut. 52(10), 1479–1486 (2003)</ref-fulltext>
<ce:source-text>Fearon, K.C.H., Von Meyenfeldt, M.F., Moses, A.G.W., Van Geenen, R., Roy, A., Gouma, D.J., et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut. 52(10), 1479–1486 (2003)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Cruz-Jentoft</ce:surname>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Baeyens</ce:surname>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bauer</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Boirie</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Cederholm</ce:surname>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>Landi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Age Ageing</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>412</first-page>
<last-page>423</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., et al.: Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 39(4), 412–423 (2010)</ref-fulltext>
<ce:source-text>Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., et al.: Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 39(4), 412–423 (2010)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting and cachexia in heart failure: Mechanisms and therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Ebner</ce:surname>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Dos Santos</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Springer</ce:surname>
</author>
<author seq="5">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>323</first-page>
<last-page>341</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Ebner, N., dos Santos, M.R., Springer, J., Anker, S.D.: Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat. Rev. Cardiol. 14(6), 323–341 (2017)</ref-fulltext>
<ce:source-text>von Haehling, S., Ebner, N., dos Santos, M.R., Springer, J., Anker, S.D.: Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat. Rev. Cardiol. 14(6), 323–341 (2017)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Myopenia—a new universal term for muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="2">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>3</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Evans, W.J., Anker, S.D.: Myopenia—a new universal term for muscle wasting. J. Cachexia. Sarcopenia Muscle. 2(1), 1–3 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., Evans, W.J., Anker, S.D.: Myopenia—a new universal term for muscle wasting. J. Cachexia. Sarcopenia Muscle. 2(1), 1–3 (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Wells</ce:surname>
</author>
<author seq="3">
<ce:initials>U.</ce:initials>
<ce:surname>Nwulu</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Currow</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>108</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1196</first-page>
<last-page>1208</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Wells, L., Nwulu, U., Currow, D., Johnson, M., Skipworth, R.: Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review. Am. J. Clin. Nutr. 108(6), 1196–1208 (2018)</ref-fulltext>
<ce:source-text>Miller, J., Wells, L., Nwulu, U., Currow, D., Johnson, M., Skipworth, R.: Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review. Am. J. Clin. Nutr. 108(6), 1196–1208 (2018)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>ESPEN expert group recommendations for action against cancer-related malnutrition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Bertz</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Bozzetti</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Calder</ce:surname>
</author>
<author seq="6">
<ce:initials>N.E.P.</ce:initials>
<ce:surname>Deutz</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1187</first-page>
<last-page>1196</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P., Deutz, N.E.P., et al.: ESPEN expert group recommendations for action against cancer-related malnutrition. Clin. Nutr. 36(5), 1187–1196 (2017)</ref-fulltext>
<ce:source-text>Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P., Deutz, N.E.P., et al.: ESPEN expert group recommendations for action against cancer-related malnutrition. Clin. Nutr. 36(5), 1187–1196 (2017)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Epidemiology of sarcopenia among the elderly in New Mexico</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Koehler</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Gallagher</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Romero</ce:surname>
</author>
<author seq="5">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
</author>
<author seq="6">
<ce:initials>R.R.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Epidemiol</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>147</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>755</first-page>
<last-page>763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumgartner, R.N., Koehler, K.M., Gallagher, D., Romero, L., Heymsfield, S.B., Ross, R.R., et al.: Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 147(8), 755–763 (1998)</ref-fulltext>
<ce:source-text>Baumgartner, R.N., Koehler, K.M., Gallagher, D., Romero, L., Heymsfield, S.B., Ross, R.R., et al.: Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 147(8), 755–763 (1998)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>The advantages and limitations of cross-sectional body composition analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="2">
<ce:initials>C.A.</ce:initials>
<ce:surname>Greig</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>342</first-page>
<last-page>349</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Greig, C.A., Baracos, V.: The advantages and limitations of cross-sectional body composition analysis. Curr. Opin. Support. Palliat. Care. 5(4), 342–349 (2011)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Greig, C.A., Baracos, V.: The advantages and limitations of cross-sectional body composition analysis. Curr. Opin. Support. Palliat. Care. 5(4), 342–349 (2011)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Appendicular skeletal muscle mass: Measurement by dual-photon absorptiometry</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Aulet</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Bensen</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Lichtman</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="1990"/>
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>218</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heymsfield, S.B., Smith, R., Aulet, M., Bensen, B., Lichtman, S., Wang, J., et al.: Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am. J. Clin. Nutr. 52(2), 214–218 (1990)</ref-fulltext>
<ce:source-text>Heymsfield, S.B., Smith, R., Aulet, M., Bensen, B., Lichtman, S., Wang, J., et al.: Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am. J. Clin. Nutr. 52(2), 214–218 (1990)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>The epidemiology of obesity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.M.</ce:initials>
<ce:surname>Nguyen</ce:surname>
</author>
<author seq="2">
<ce:initials>H.B.</ce:initials>
<ce:surname>El-Serag</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Gastroenterol Clin North Am</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>7</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.M., El-Serag, H.B.: The epidemiology of obesity. Gastroenterol Clin North Am. 39(1), 1–7 (2010)</ref-fulltext>
<ce:source-text>Nguyen, D.M., El-Serag, H.B.: The epidemiology of obesity. Gastroenterol Clin North Am. 39(1), 1–7 (2010)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Flegal</ce:surname>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Carroll</ce:surname>
</author>
<author seq="3">
<ce:initials>B.K.</ce:initials>
<ce:surname>Kit</ce:surname>
</author>
<author seq="4">
<ce:initials>C.L.</ce:initials>
<ce:surname>Ogden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JAMA</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>307</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L.: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 307(5), 491–497 (2012)</ref-fulltext>
<ce:source-text>Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L.: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 307(5), 491–497 (2012)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Risk factor paradox in wasting diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kalantar-Zadeh</ce:surname>
</author>
<author seq="2">
<ce:initials>T.B.</ce:initials>
<ce:surname>Horwich</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Oreopoulos</ce:surname>
</author>
<author seq="4">
<ce:initials>C.P.</ce:initials>
<ce:surname>Kovesdy</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Younessi</ce:surname>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
<author seq="7">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr Opin Clin Nutr Metab Care</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>442</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalantar-Zadeh, K., Horwich, T.B., Oreopoulos, A., Kovesdy, C.P., Younessi, H., Anker, S.D., Morley, J.E.: Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 10(4), 433–442 (2007)</ref-fulltext>
<ce:source-text>Kalantar-Zadeh, K., Horwich, T.B., Oreopoulos, A., Kovesdy, C.P., Younessi, H., Anker, S.D., Morley, J.E.: Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 10(4), 433–442 (2007)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Diagnostic criteria for the classification of cancer-associated weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Senesse</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Gioulbasanis</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Antoun</ce:surname>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:surname>Bozzetti</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
</author>
<author seq="7">
<ce:initials>F.</ce:initials>
<ce:surname>Strasser</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Thoresen</ce:surname>
</author>
<author seq="9">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Chasen</ce:surname>
</author>
<author seq="11">
<ce:initials>K.</ce:initials>
<ce:surname>Lundholm</ce:surname>
</author>
<author seq="12">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
</author>
<author seq="13">
<ce:initials>K.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="14">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>99</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R.T., Chasen, M., Lundholm, K., Bosaeus, I., Fearon, K.H., Baracos, V.E.: Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 33(1), 90–99 (2015)</ref-fulltext>
<ce:source-text>Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R.T., Chasen, M., Lundholm, K., Bosaeus, I., Fearon, K.H., Baracos, V.E.: Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 33(1), 90–99 (2015)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Health, Aging, and Body: Longitudinal study of muscle strength, quality, and adipose tissue infiltration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Delmonico</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Harris</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Visser</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Conroy</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Velasquez-Mieyer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1579</first-page>
<last-page>1585</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Delmonico, M., Harris, T., Visser, M., Park, S., Conroy, M., Velasquez-Mieyer, P., et al.: Health, Aging, and Body: longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am. J. Clin. Nutr. 90, 1579–1585 (2009)</ref-fulltext>
<ce:source-text>Delmonico, M., Harris, T., Visser, M., Park, S., Conroy, M., Velasquez-Mieyer, P., et al.: Health, Aging, and Body: longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am. J. Clin. Nutr. 90, 1579–1585 (2009)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal intramyocellular lipid metabolism and insulin resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Yi</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Cichello</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biophys. Rev</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>98</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y., Xu, S., Zhang, X., Yi, Z., Cichello, S.: Skeletal intramyocellular lipid metabolism and insulin resistance. Biophys. Rev. 1, 90–98 (2015)</ref-fulltext>
<ce:source-text>Li, Y., Xu, S., Zhang, X., Yi, Z., Cichello, S.: Skeletal intramyocellular lipid metabolism and insulin resistance. Biophys. Rev. 1, 90–98 (2015)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Gray</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Macgillivray</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Eeley</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Beggs</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>106</first-page>
<last-page>111</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gray, C., MacGillivray, T., Eeley, C., Stephens, N., Beggs, I., Fearon, K., et al.: Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin. Nutr. 30, 106–111 (2011)</ref-fulltext>
<ce:source-text>Gray, C., MacGillivray, T., Eeley, C., Stephens, N., Beggs, I., Fearon, K., et al.: Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin. Nutr. 30, 106–111 (2011)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Intramyocellular lipid droplets increase with progression of cachexia in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Greig</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>111</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N., Skipworth, R., MacDonald, A., Greig, C., Ross, J., Fearon, K.: Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia. Sarcopenia Muscle. 2, 111–117 (2011)</ref-fulltext>
<ce:source-text>Stephens, N., Skipworth, R., MacDonald, A., Greig, C., Ross, J., Fearon, K.: Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia. Sarcopenia Muscle. 2, 111–117 (2011)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.I.</ce:initials>
<ce:surname>Ramage</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="3">
<ce:initials>C.D.A.</ce:initials>
<ce:surname>Deans</ce:surname>
</author>
<author seq="4">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
</author>
<author seq="6">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2016"/>
</ref-info>
<ref-fulltext>Ramage, M.I., Johns, N., Deans, C.D.A., Ross, J.A., Preston, T., Skipworth, R.J.E., et al.: The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. Clin. Nutr. Edinb. Scotl. (2016 Dec 27)</ref-fulltext>
<ce:source-text>Ramage, M.I., Johns, N., Deans, C.D.A., Ross, J.A., Preston, T., Skipworth, R.J.E., et al.: The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. Clin. Nutr. Edinb. Scotl. (2016 Dec 27)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Subcutaneous adiposity is an independent predictor of mortality in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
<author seq="4">
<ce:initials>C.J.</ce:initials>
<ce:surname>Field</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Lehner</ce:surname>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="7">
<ce:initials>V.C.</ce:initials>
<ce:surname>Mazurak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br J Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>148</first-page>
<last-page>155</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Martin, L., Ghosh, S., Field, C.J., Lehner, R., Baracos, V.E., Mazurak, V.C.: Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 117(1), 148–155 (2017)</ref-fulltext>
<ce:source-text>Ebadi, M., Martin, L., Ghosh, S., Field, C.J., Lehner, R., Baracos, V.E., Mazurak, V.C.: Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 117(1), 148–155 (2017)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging body composition in cancer patients: Visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Yip</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Dinkel</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Mahajan</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Siddique</ce:surname>
</author>
<author seq="5">
<ce:initials>G.J.R.</ce:initials>
<ce:surname>Cook</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Goh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Insights Imaging</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yip, C., Dinkel, C., Mahajan, A., Siddique, M., Cook, G.J.R., Goh, V.: Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 6(4), 489–497 (2015)</ref-fulltext>
<ce:source-text>Yip, C., Dinkel, C., Mahajan, A., Siddique, M., Cook, G.J.R., Goh, V.: Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 6(4), 489–497 (2015)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle shape consistency and muscle volume prediction of thigh muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Mersmann</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bohm</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schroll</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Boeth</ce:surname>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Duda</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Arampatzis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Scand. J. Med. Sci. Sports</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e208</first-page>
<last-page>e213</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mersmann, F., Bohm, S., Schroll, A., Boeth, H., Duda, G., Arampatzis, A.: Muscle shape consistency and muscle volume prediction of thigh muscles. Scand. J. Med. Sci. Sports. 25(2), e208–e213 (2015)</ref-fulltext>
<ce:source-text>Mersmann, F., Bohm, S., Schroll, A., Boeth, H., Duda, G., Arampatzis, A.: Muscle shape consistency and muscle volume prediction of thigh muscles. Scand. J. Med. Sci. Sports. 25(2), e208–e213 (2015)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Willis</ce:surname>
</author>
<author seq="2">
<ce:initials>K.G.</ce:initials>
<ce:surname>Hollingsworth</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Coombs</ce:surname>
</author>
<author seq="4">
<ce:initials>M.L.</ce:initials>
<ce:surname>Sveen</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Stojkovic</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One [Internet]</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Willis, T.A., Hollingsworth, K.G., Coombs, A., Sveen, M.L., Andersen, S., Stojkovic, T., et al.: Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study. PLoS One [Internet]. (2013 Aug 14) [cited 2016 May 18];8(8). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ref-fulltext>
<ce:source-text>Willis, T.A., Hollingsworth, K.G., Coombs, A., Sveen, M.L., Andersen, S., Stojkovic, T., et al.: Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study. PLoS One [Internet]. (2013 Aug 14) [cited 2016 May 18];8(8). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Karlsson</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Rosander</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Romu</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Tallberg</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Grönqvist</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Borga</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Magn. Reson. Imaging</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>41</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1558</first-page>
<last-page>1569</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Karlsson, A., Rosander, J., Romu, T., Tallberg, J., Grönqvist, A., Borga, M., et al.: Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI. J. Magn. Reson. Imaging. 41(6), 1558–1569 (2015)</ref-fulltext>
<ce:source-text>Karlsson, A., Rosander, J., Romu, T., Tallberg, J., Grönqvist, A., Borga, M., et al.: Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI. J. Magn. Reson. Imaging. 41(6), 1558–1569 (2015)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.E.</ce:initials>
<ce:surname>Rollins</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Tewari</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Ackner</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Awwad</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Madhusudan</ce:surname>
</author>
<author seq="6">
<ce:initials>I.A.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1103</first-page>
<last-page>1109</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rollins, K.E., Tewari, N., Ackner, A., Awwad, A., Madhusudan, S., Macdonald, I.A., et al.: The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin. Nutr. Edinb. Scotl. 35(5), 1103–1109 (2016)</ref-fulltext>
<ce:source-text>Rollins, K.E., Tewari, N., Ackner, A., Awwad, A., Madhusudan, S., Macdonald, I.A., et al.: The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin. Nutr. Edinb. Scotl. 35(5), 1103–1109 (2016)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Weber</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Krakowski-Roosen</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Schroder</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Kinscherf</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Krix</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kopp-Schneider</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>116</first-page>
<last-page>124</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weber, M., Krakowski-Roosen, H., Schroder, L., Kinscherf, R., Krix, M., Kopp-Schneider, A., et al.: Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 48(1), 116–124 (2009)</ref-fulltext>
<ce:source-text>Weber, M., Krakowski-Roosen, H., Schroder, L., Kinscherf, R., Krix, M., Kopp-Schneider, A., et al.: Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 48(1), 116–124 (2009)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Krix</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Krakowski-Roosen</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Huttner</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Delorme</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Kauczor</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Hildebrandt</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Ultrasound Med</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>441</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Krix, M., Krakowski-Roosen, H., Huttner, H., Delorme, S., Kauczor, H., Hildebrandt, W.: Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography. J. Ultrasound Med. 24(4), 431–441 (2005)</ref-fulltext>
<ce:source-text>Krix, M., Krakowski-Roosen, H., Huttner, H., Delorme, S., Kauczor, H., Hildebrandt, W.: Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography. J. Ultrasound Med. 24(4), 431–441 (2005)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Sabatino</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Regolistil</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Bozzoli</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Fani</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Antoniotti</ce:surname>
</author>
<author seq="6">
<ce:initials>U.</ce:initials>
<ce:surname>Maggiore</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1710</first-page>
<last-page>1715</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sabatino, A., Regolistil, G., Bozzoli, L., Fani, F., Antoniotti, R., Maggiore, U., et al.: Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury. Clin. Nutr. 36(6), 1710–1715 (2017)</ref-fulltext>
<ce:source-text>Sabatino, A., Regolistil, G., Bozzoli, L., Fani, F., Antoniotti, R., Maggiore, U., et al.: Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury. Clin. Nutr. 36(6), 1710–1715 (2017)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Qualitative ultrasound in acute critical illness muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Puthucheary</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Phadke</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Rawal</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>McPhail</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Sidhu</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Rowlerson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Crit. Care Med</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>43</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1603</first-page>
<last-page>1611</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puthucheary, Z., Phadke, R., Rawal, J., McPhail, M., Sidhu, P., Rowlerson, A., et al.: Qualitative ultrasound in acute critical illness muscle wasting. Crit. Care Med. 43(8), 1603–1611 (2015)</ref-fulltext>
<ce:source-text>Puthucheary, Z., Phadke, R., Rawal, J., McPhail, M., Sidhu, P., Rowlerson, A., et al.: Qualitative ultrasound in acute critical illness muscle wasting. Crit. Care Med. 43(8), 1603–1611 (2015)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Gray</ce:surname>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="4">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
</author>
<author seq="5">
<ce:initials>I.J.</ce:initials>
<ce:surname>Gallagher</ce:surname>
</author>
<author seq="6">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nutr</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>499</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J.E., et al.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31(4), 499–505 (2012)</ref-fulltext>
<ce:source-text>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J.E., et al.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31(4), 499–505 (2012)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Moses</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sangster</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Voss</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Fallon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>391</first-page>
<last-page>401</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skipworth, R.J.E., Moses, A., Sangster, K., Sturgeon, C., Voss, A., Fallon, M., et al.: Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 19(3), 391–401 (2011)</ref-fulltext>
<ce:source-text>Skipworth, R.J.E., Moses, A., Sangster, K., Sturgeon, C., Voss, A., Fallon, M., et al.: Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 19(3), 391–401 (2011)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Rejtar</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Reinker</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Brachat</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Badur</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stretch, C., Wang, K., Rejtar, T., Reinker, S., Brachat, S., Badur, R., et al.: Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients. J. Cachexia. Sarcopenia Muscle. 9(1), 183–212 (2018)</ref-fulltext>
<ce:source-text>Stretch, C., Wang, K., Rejtar, T., Reinker, S., Brachat, S., Badur, R., et al.: Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients. J. Cachexia. Sarcopenia Muscle. 9(1), 183–212 (2018)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
</author>
<author seq="3">
<ce:initials>B.H.L.</ce:initials>
<ce:surname>Tan</ce:surname>
</author>
<author seq="4">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Sørhaug</ce:surname>
</author>
<author seq="6">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Cachexia Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
</ref-info>
<ref-fulltext>Johns, N., Stretch, C., Tan, B.H.L., Solheim, T.S., Sørhaug, S., Stephens, N.A., et al.: New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle. (2016 Jan 1);n/a–n/a</ref-fulltext>
<ce:source-text>Johns, N., Stretch, C., Tan, B.H.L., Solheim, T.S., Sørhaug, S., Stephens, N.A., et al.: New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle. (2016 Jan 1);n/a–n/a</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Rose-Zerilli</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Howell</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Jackson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg. Oncol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>339</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deans, C., Rose-Zerilli, M., Wigmore, S.,Ross, J., Howell, M., Jackson, A., et al.: Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann. Surg. Oncol. 14(2), 329–339 (2007)</ref-fulltext>
<ce:source-text>Deans, C., Rose-Zerilli, M., Wigmore, S.,Ross, J., Howell, M., Jackson, A., et al.: Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann. Surg. Oncol. 14(2), 329–339 (2007)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barber</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Powell</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lynch</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>83</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1443</first-page>
<last-page>1447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barber, M., Powell, J., Lynch, S., Fearon, K., Ross, J.: A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer. 83, 1443–1447 (2000)</ref-fulltext>
<ce:source-text>Barber, M., Powell, J., Lynch, S., Fearon, K., Ross, J.: A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer. 83, 1443–1447 (2000)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barber</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Powell</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lynch</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Gough</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Immunol</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>425</first-page>
<last-page>429</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barber, M., Powell, J., Lynch, S., Gough, N., Fearon, K., Ross, J.: Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin. Exp. Immunol. 117, 425–429 (1999)</ref-fulltext>
<ce:source-text>Barber, M., Powell, J., Lynch, S., Gough, N., Fearon, K., Ross, J.: Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin. Exp. Immunol. 117, 425–429 (1999)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia and pancreatic cancer: Are there treatment options? World</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mueller</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Burmeister</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Bachmann</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Martignoni</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9361</first-page>
<last-page>9373</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mueller, T., Burmeister, M., Bachmann, J., Martignoni, M.: Cachexia and pancreatic cancer: Are there treatment options? World J. Gastroenterol. 20(28), 9361–9373 (2014)</ref-fulltext>
<ce:source-text>Mueller, T., Burmeister, M., Bachmann, J., Martignoni, M.: Cachexia and pancreatic cancer: Are there treatment options? World J. Gastroenterol. 20(28), 9361–9373 (2014)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Vazeille</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Jouinot</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Durand</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Neveux</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Boudou-Rouquette</ce:surname>
</author>
<author seq="6">
<ce:initials>O.</ce:initials>
<ce:surname>Huillard</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1139</first-page>
<last-page>1147</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vazeille, C., Jouinot, A., Durand, J., Neveux, N., Boudou-Rouquette, P., Huillard, O., et al.: Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy. Am. J. Clin. Nutr. 105(5), 1139–1147 (2017)</ref-fulltext>
<ce:source-text>Vazeille, C., Jouinot, A., Durand, J., Neveux, N., Boudou-Rouquette, P., Huillard, O., et al.: Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy. Am. J. Clin. Nutr. 105(5), 1139–1147 (2017)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>van Dijk</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Horstman</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Smeets</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Den Dulk</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Grabsch</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Dejong</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>van Dijk, D., Horstman, A., Smeets, J., den Dulk, M., Grabsch, H., Dejong, C., et al.: Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 10(3) (2019)</ref-fulltext>
<ce:source-text>van Dijk, D., Horstman, A., Smeets, J., den Dulk, M., Grabsch, H., Dejong, C., et al.: Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 10(3) (2019)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>van Dijk</ce:surname>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Van de Poll</ce:surname>
</author>
<author seq="3">
<ce:initials>A.G.</ce:initials>
<ce:surname>Moses</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
</author>
<author seq="5">
<ce:initials>S.W.</ce:initials>
<ce:surname>Olde Damink</ce:surname>
</author>
<author seq="6">
<ce:initials>S.S.</ce:initials>
<ce:surname>Rensen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>212</first-page>
<last-page>221</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van Dijk, D.P., van de Poll, M.C., Moses, A.G., Preston, T., Olde Damink, S.W., Rensen, S.S., et al.: Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 6(3), 212–221 (2015)</ref-fulltext>
<ce:source-text>van Dijk, D.P., van de Poll, M.C., Moses, A.G., Preston, T., Olde Damink, S.W., Rensen, S.S., et al.: Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 6(3), 212–221 (2015)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.E.P.</ce:initials>
<ce:surname>Deutz</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Safar</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Schutzler</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Memelink</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Ferrando</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Spencer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>759</first-page>
<last-page>768</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deutz, N.E.P., Safar, A., Schutzler, S., Memelink, R., Ferrando, A., Spencer, H., et al.: Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin. Nutr. Edinb. Scotl. 30(6), 759–768 (2011)</ref-fulltext>
<ce:source-text>Deutz, N.E.P., Safar, A., Schutzler, S., Memelink, R., Ferrando, A., Spencer, H., et al.: Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin. Nutr. Edinb. Scotl. 30(6), 759–768 (2011)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Small</ce:surname>
</author>
<author seq="3">
<ce:initials>C.A.</ce:initials>
<ce:surname>Greig</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Husi</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="6">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rapid. Commun. Mass Spectrom. RCM</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1769</first-page>
<last-page>1777</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Small, A.C., Greig, C.A., Husi, H., Ross, J.A., Stephens, N.A., et al.: A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis. Rapid. Commun. Mass Spectrom. RCM. 27(15), 1769–1777 (2013)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Small, A.C., Greig, C.A., Husi, H., Ross, J.A., Stephens, N.A., et al.: A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis. Rapid. Commun. Mass Spectrom. RCM. 27(15), 1769–1777 (2013)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Greig</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="6">
<ce:initials>A.C.</ce:initials>
<ce:surname>Small</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. Assoc. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1734</first-page>
<last-page>1740</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Johns, N., Stephens, N., Greig, C., Ross, J.A., Small, A.C., et al.: Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Am. Assoc. Cancer Res. 21(7), 1734–1740 (2015)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Johns, N., Stephens, N., Greig, C., Ross, J.A., Small, A.C., et al.: Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Am. Assoc. Cancer Res. 21(7), 1734–1740 (2015)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sandri, M.: Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45(10) (2013)</ref-fulltext>
<ce:source-text>Sandri, M.: Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45(10) (2013)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Coming back: Autophagy in cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Baccino</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>241</first-page>
<last-page>246</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., Baccino, F., Costelli, P.: Coming back: Autophagy in cachexia. Curr. Opin. Clin. Nutr. Metab. Care. 17(3), 241–246 (2014)</ref-fulltext>
<ce:source-text>Penna, F., Baccino, F., Costelli, P.: Coming back: Autophagy in cachexia. Curr. Opin. Clin. Nutr. Metab. Care. 17(3), 241–246 (2014)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>The impact of autophagy on cell death modalities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Ryter</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Mizumura</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Choi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
</ref-info>
<ref-fulltext>Ryter, S., Mizumura, K., Choi, A.: The impact of autophagy on cell death modalities. Int. J. Cell Biol. (2014)</ref-fulltext>
<ce:source-text>Ryter, S., Mizumura, K., Choi, A.: The impact of autophagy on cell death modalities. Int. J. Cell Biol. (2014)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pettersen</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<author seq="4">
<ce:initials>V.</ce:initials>
<ce:surname>Tadini</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Grosjean</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2046</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pettersen, K., Andersen, S., Degen, S., Tadini, V., Grosjean, J., Hatakeyama, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling. Sci. Rep. 7, 2046 (2017)</ref-fulltext>
<ce:source-text>Pettersen, K., Andersen, S., Degen, S., Tadini, V., Grosjean, J., Hatakeyama, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling. Sci. Rep. 7, 2046 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
</author>
<author seq="3">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Frieauff</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Johns, N., Hatakeyama, S., Stephens, N.A., Degen, M., Degen, S., Frieauff, W., et al.: Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle. PLoS One. 9(1), e83618 (2014)</ref-fulltext>
<ce:source-text>Johns, N., Hatakeyama, S., Stephens, N.A., Degen, M., Degen, S., Frieauff, W., et al.: Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle. PLoS One. 9(1), e83618 (2014)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular junctions are stable in patients with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Boehm</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Wishart</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Jones</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Boehm, I., Miller, J., Wishart, T., Wigmore, S., Skipworth, R., Jones, R., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ref-fulltext>
<ce:source-text>Boehm, I., Miller, J., Wishart, T., Wigmore, S., Skipworth, R., Jones, R., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence and mechanisms of fat depletion in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
</author>
<author seq="2">
<ce:initials>V.C.</ce:initials>
<ce:surname>Mazurak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nutrients</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5280</first-page>
<last-page>5297</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Mazurak, V.C.: Evidence and mechanisms of fat depletion in cancer. Nutrients. 6(11), 5280–5297 (2014)</ref-fulltext>
<ce:source-text>Ebadi, M., Mazurak, V.C.: Evidence and mechanisms of fat depletion in cancer. Nutrients. 6(11), 5280–5297 (2014)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ryden</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Agustsson</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Laurencikiene</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Britton</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Sjolin</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Isaksson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>113</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1695</first-page>
<last-page>1704</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ryden, M., Agustsson, T., Laurencikiene, J., Britton, T., Sjolin, E., Isaksson, B., et al.: Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia. Cancer. 113(7), 1695–1704 (2008)</ref-fulltext>
<ce:source-text>Ryden, M., Agustsson, T., Laurencikiene, J., Britton, T., Sjolin, E., Isaksson, B., et al.: Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia. Cancer. 113(7), 1695–1704 (2008)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mracek</ce:surname>
</author>
<author seq="2">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Bao</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Rydén</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>104</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mracek, T., Stephens, N.A., Gao, D., Bao, Y., Ross, J.A., Rydén, M., et al.: Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br. J. Cancer. 104(3), 441–447 (2011)</ref-fulltext>
<ce:source-text>Mracek, T., Stephens, N.A., Gao, D., Bao, Y., Ross, J.A., Rydén, M., et al.: Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br. J. Cancer. 104(3), 441–447 (2011)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Bathe</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Robinson</ce:surname>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:surname>Mazurak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1347</first-page>
<last-page>1353</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Baracos, V., Bathe, O., Robinson, L., Mazurak, V.: Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content. Clin. Nutr. 35(6), 1347–1353 (2016)</ref-fulltext>
<ce:source-text>Ebadi, M., Baracos, V., Bathe, O., Robinson, L., Mazurak, V.: Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content. Clin. Nutr. 35(6), 1347–1353 (2016)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Not all fat is equal: Differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Modesitt</ce:surname>
</author>
<author seq="2">
<ce:initials>J.Y.</ce:initials>
<ce:surname>Hsu</ce:surname>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Chowbina</ce:surname>
</author>
<author seq="4">
<ce:initials>R.T.</ce:initials>
<ce:surname>Lawrence</ce:surname>
</author>
<author seq="5">
<ce:initials>K.L.</ce:initials>
<ce:surname>Hoehn</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>732</first-page>
<last-page>741</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Modesitt, S.C., Hsu, J.Y., Chowbina, S.R., Lawrence, R.T., Hoehn, K.L.: Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 22(5), 732–741 (2012)</ref-fulltext>
<ce:source-text>Modesitt, S.C., Hsu, J.Y., Chowbina, S.R., Lawrence, R.T., Hoehn, K.L.: Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 22(5), 732–741 (2012)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Adipose triglyceride lipase contributes to cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Das</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Eder</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Schauer</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Diwoky</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Temmel</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Guertl</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>333</vol-first>
<iss-first>6039</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>233</first-page>
<last-page>238</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Das, S.K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ref-fulltext>
<ce:source-text>Das, S.K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kir</ce:surname>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kleiner</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>513</vol-first>
<iss-first>7516</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ref-fulltext>
<ce:source-text>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Paterson-Brown</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Black</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="6">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1810</first-page>
<last-page>1818</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deans, C., Wigmore, S., Paterson-Brown, S., Black, J., Ross, J., Fearon, K.C.H.: Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer. 103(9), 1810–1818 (2005)</ref-fulltext>
<ce:source-text>Deans, C., Wigmore, S., Paterson-Brown, S., Black, J., Ross, J., Fearon, K.C.H.: Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer. 103(9), 1810–1818 (2005)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kir</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Komaba</ce:surname>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Garcia</ce:surname>
</author>
<author seq="4">
<ce:initials>K.P.</ce:initials>
<ce:surname>Economopoulos</ce:surname>
</author>
<author seq="5">
<ce:initials>W.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Lanske</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>315</first-page>
<last-page>323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kir, S., Komaba, H., Garcia, A.P., Economopoulos, K.P., Liu, W., Lanske, B., et al.: PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23(2), 315–323 (2016)</ref-fulltext>
<ce:source-text>Kir, S., Komaba, H., Garcia, A.P., Economopoulos, K.P., Liu, W., Lanske, B., et al.: PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23(2), 315–323 (2016)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Chicheportiche</ce:surname>
</author>
<author seq="2">
<ce:initials>P.R.</ce:initials>
<ce:surname>Bourdon</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.M.</ce:initials>
<ce:surname>Hsu</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Scott</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Hession</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32401</first-page>
<last-page>32410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.M., Scott, H., Hession, C., et al.: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272(51), 32401–32410 (1997)</ref-fulltext>
<ce:source-text>Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.M., Scott, H., Hession, C., et al.: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272(51), 32401–32410 (1997)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Dogra</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Changotra</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Wedhas</ce:surname>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Qin</ce:surname>
</author>
<author seq="5">
<ce:initials>J.E.</ce:initials>
<ce:surname>Wergedal</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1857</first-page>
<last-page>1869</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J.E., Kumar, A.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21(8), 1857–1869 (2007)</ref-fulltext>
<ce:source-text>Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J.E., Kumar, A.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21(8), 1857–1869 (2007)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.</ce:initials>
<ce:surname>Wiley</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Cassiano</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Lofton</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Davis-Smith</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Winkles</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Lindner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>837</first-page>
<last-page>846</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wiley, S.R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J.A., Lindner, V., et al.: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 15(5), 837–846 (2001)</ref-fulltext>
<ce:source-text>Wiley, S.R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J.A., Lindner, V., et al.: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 15(5), 837–846 (2001)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.L.Y.</ce:initials>
<ce:surname>Feng</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Guo</ce:surname>
</author>
<author seq="3">
<ce:initials>V.M.</ce:initials>
<ce:surname>Factor</ce:surname>
</author>
<author seq="4">
<ce:initials>S.S.</ce:initials>
<ce:surname>Thorgeirsson</ce:surname>
</author>
<author seq="5">
<ce:initials>D.W.</ce:initials>
<ce:surname>Bell</ce:surname>
</author>
<author seq="6">
<ce:initials>J.R.</ce:initials>
<ce:surname>Testa</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>156</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1253</first-page>
<last-page>1261</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Feng, S.L.Y., Guo, Y., Factor, V.M., Thorgeirsson, S.S., Bell, D.W., Testa, J.R., et al.: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am. J. Pathol. 156(4), 1253–1261 (2000)</ref-fulltext>
<ce:source-text>Feng, S.L.Y., Guo, Y., Factor, V.M., Thorgeirsson, S.S., Bell, D.W., Testa, J.R., et al.: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am. J. Pathol. 156(4), 1253–1261 (2000)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>The TWEAK–Fn14 cytokine–receptor axis: Discovery, biology and therapeutic targeting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Winkles</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Winkles, J.A.: The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7(5), 411–425 (2008)</ref-fulltext>
<ce:source-text>Winkles, J.A.: The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7(5), 411–425 (2008)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: Insights from two exercise modes and a time course investigation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Raue</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Jemiolo</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Trappe</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>569</first-page>
<last-page>578</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Raue, U., Jemiolo, B., Yang, Y., Trappe, S.: TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: insights from two exercise modes and a time course investigation. J. Appl. Physiol. 118(5), 569–578 (2015)</ref-fulltext>
<ce:source-text>Raue, U., Jemiolo, B., Yang, Y., Trappe, S.: TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: insights from two exercise modes and a time course investigation. J. Appl. Physiol. 118(5), 569–578 (2015)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Bhatnagar</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Mittal</ce:surname>
</author>
<author seq="3">
<ce:initials>S.K.</ce:initials>
<ce:surname>Gupta</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>227</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1042</first-page>
<last-page>1051</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhatnagar, S., Mittal, A., Gupta, S.K., Kumar, A.: TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J. Cell. Physiol. 227(3), 1042–1051 (2012)</ref-fulltext>
<ce:source-text>Bhatnagar, S., Mittal, A., Gupta, S.K., Kumar, A.: TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J. Cell. Physiol. 227(3), 1042–1051 (2012)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Johnston</ce:surname>
</author>
<author seq="2">
<ce:initials>K.T.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Jenkinson</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Laine</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Emmrich</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Faou</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>162</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1365</first-page>
<last-page>1378</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnston, A.J., Murphy, K.T., Jenkinson, L., Laine, D., Emmrich, K., Faou, P., et al.: Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 162(6), 1365–1378 (2015)</ref-fulltext>
<ce:source-text>Johnston, A.J., Murphy, K.T., Jenkinson, L., Laine, D., Emmrich, K., Faou, P., et al.: Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 162(6), 1365–1378 (2015)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Biswas</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Kandpal</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Cocker</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Grandgenett</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., Biswas, A., Ma, W., Kandpal, M., Cocker, C., Grandgenett, P., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., Biswas, A., Ma, W., Kandpal, M., Cocker, C., Grandgenett, P., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Shakri</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Zhong</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Coker</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Calluori</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shakri, A., Zhong, T., Ma, W., Coker, C., Kim, S., Calluori, S., et al.: Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers. 18(12), 3 (2019)</ref-fulltext>
<ce:source-text>Shakri, A., Zhong, T., Ma, W., Coker, C., Kim, S., Calluori, S., et al.: Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers. 18(12), 3 (2019)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>The MIC-1/GDF15-GFRAL pathway in energy homeostasis: Implications for obesity, cachexia, and other associated diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Tsai</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Husaini</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Sainsbury</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Brown</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Breit</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>353</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsai, V., Husaini, Y., Sainsbury, A., Brown, D., Breit, S.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018)</ref-fulltext>
<ce:source-text>Tsai, V., Husaini, Y., Sainsbury, A., Brown, D., Breit, S.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sadasivan</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Gupta</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Taneja</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Maresh</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>421</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sadasivan, S., Chen, Y., Gupta, N., Taneja, K., Maresh, S., Gonzalez, A., et al.: The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis. Cancer Res. 78, 421 (2018)</ref-fulltext>
<ce:source-text>Sadasivan, S., Chen, Y., Gupta, N., Taneja, K., Maresh, S., Gonzalez, A., et al.: The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis. Cancer Res. 78, 421 (2018)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>GDF15 induces anorexia through nausea and emesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Shaulson</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Ghidewon</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Barnett</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Horn</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Doyle</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>351</first-page>
<last-page>362</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borner, T., Shaulson, E., Ghidewon, M., Barnett, A., Horn, C., Doyle, R., et al.: GDF15 induces anorexia through nausea and emesis. Cell Metab. 31(2), 351–362 (2020)</ref-fulltext>
<ce:source-text>Borner, T., Shaulson, E., Ghidewon, M., Barnett, A., Horn, C., Doyle, R., et al.: GDF15 induces anorexia through nausea and emesis. Cell Metab. 31(2), 351–362 (2020)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Blocking extracellular activation of myostatin as a strategy for treating muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Pirruccello-Straub</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Jackson</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Wawersik</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Webster</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Salta</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Long</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2292</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, T., Salta, L., Long, K., et al.: Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 8, 2292 (2018)</ref-fulltext>
<ce:source-text>Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, T., Salta, L., Long, K., et al.: Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 8, 2292 (2018)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Walton</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Hagg</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Colgan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>PNAS</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5266</first-page>
<last-page>5275</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J., Walton, K., Hagg, A., Colgan, T.: Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. PNAS. 114(26), 5266–5275 (2017)</ref-fulltext>
<ce:source-text>Chen, J., Walton, K., Hagg, A., Colgan, T.: Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. PNAS. 114(26), 5266–5275 (2017)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sin</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>202</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, H., Zhang, G., Sin, K., Liu, Z.: Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase. J. Cachexia. Sarcopenia Muscle. 8(2), 202–212 (2017)</ref-fulltext>
<ce:source-text>Ding, H., Zhang, G., Sin, K., Liu, Z.: Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase. J. Cachexia. Sarcopenia Muscle. 8(2), 202–212 (2017)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Morvan</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Rondeau</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Zou</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Minetti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>47</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>12448</first-page>
<last-page>12453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morvan, F., Rondeau, J., Zou, C., Minetti, G.: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc. Natl. Acad. Sci. USA. 114(47), 12448–12453 (2017)</ref-fulltext>
<ce:source-text>Morvan, F., Rondeau, J., Zou, C., Minetti, G.: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc. Natl. Acad. Sci. USA. 114(47), 12448–12453 (2017)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Golan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Geva</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Richards</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Madhusudan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>871</first-page>
<last-page>879</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Golan, T., Geva, R., Richards, D., Madhusudan, S.: LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial. J. Cachexia. Sarcopenia Muscle. 9(5), 871–879 (2018)</ref-fulltext>
<ce:source-text>Golan, T., Geva, R., Richards, D., Madhusudan, S.: LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial. J. Cachexia. Sarcopenia Muscle. 9(5), 871–879 (2018)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Becker</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Lord</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Studenski</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Warden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Diabetes Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>948</first-page>
<last-page>957</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Becker, C., Lord, S., Studenski, S., Warden, S.: Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 3(12), 948–957 (2015)</ref-fulltext>
<ce:source-text>Becker, C., Lord, S., Studenski, S., Warden, S.: Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 3(12), 948–957 (2015)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Brink</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wellen</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Delafontaine</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2509</first-page>
<last-page>2516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brink, M., Wellen, J., Delafontaine, P.: Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97(11), 2509–2516 (1996)</ref-fulltext>
<ce:source-text>Brink, M., Wellen, J., Delafontaine, P.: Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97(11), 2509–2516 (1996)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.Q.</ce:initials>
<ce:surname>Adigun</ce:surname>
</author>
<author seq="2">
<ce:initials>A.A.</ce:initials>
<ce:surname>Ajayi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Heart Fail</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>359</first-page>
<last-page>363</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Adigun, A.Q., Ajayi, A.A.: The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia. Eur. J. Heart Fail. 3(3), 359–363 (2001)</ref-fulltext>
<ce:source-text>Adigun, A.Q., Ajayi, A.A.: The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia. Eur. J. Heart Fail. 3(3), 359–363 (2001)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II directly inhibits protein synthesis in murine myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.T.</ce:initials>
<ce:surname>Russell</ce:surname>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:surname>Sanders</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>231</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>290</first-page>
<last-page>294</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Russell, S.T., Sanders, P.M., Tisdale, M.J.: Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231(2), 290–294 (2006)</ref-fulltext>
<ce:source-text>Russell, S.T., Sanders, P.M., Tisdale, M.J.: Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231(2), 290–294 (2006)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.M.</ce:initials>
<ce:surname>Sanders</ce:surname>
</author>
<author seq="2">
<ce:initials>S.T.</ce:initials>
<ce:surname>Russell</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>425</first-page>
<last-page>434</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanders, P.M., Russell, S.T., Tisdale, M.J.: Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer. 93(4), 425–434 (2005)</ref-fulltext>
<ce:source-text>Sanders, P.M., Russell, S.T., Tisdale, M.J.: Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer. 93(4), 425–434 (2005)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshida</ce:surname>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Tabony</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Galvez</ce:surname>
</author>
<author seq="4">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
</author>
<author seq="5">
<ce:initials>Y.</ce:initials>
<ce:surname>Higashi</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Sukhanov</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2322</first-page>
<last-page>2332</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshida, T., Tabony, A.M., Galvez, S., Mitch, W.E., Higashi, Y., Sukhanov, S., et al.: Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int. J. Biochem. Cell Biol. 45(10), 2322–2332 (2013)</ref-fulltext>
<ce:source-text>Yoshida, T., Tabony, A.M., Galvez, S., Mitch, W.E., Higashi, Y., Sukhanov, S., et al.: Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int. J. Biochem. Cell Biol. 45(10), 2322–2332 (2013)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Penafuerte</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Gagnon</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Sirois</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="6">
<ce:initials>M.L.</ce:initials>
<ce:surname>Tremblay</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>680</first-page>
<last-page>687</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penafuerte, C.A., Gagnon, B., Sirois, J., Murphy, J., MacDonald, N., Tremblay, M.L.: Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br. J. Cancer. 114(6), 680–687 (2016)</ref-fulltext>
<ce:source-text>Penafuerte, C.A., Gagnon, B., Sirois, J., Murphy, J., MacDonald, N., Tremblay, M.L.: Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br. J. Cancer. 114(6), 680–687 (2016)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Negassa</ce:surname>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>Coats</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Afzal</ce:surname>
</author>
<author seq="5">
<ce:initials>P.A.</ce:initials>
<ce:surname>Poole-Wilson</ce:surname>
</author>
<author seq="6">
<ce:initials>J.N.</ce:initials>
<ce:surname>Cohn</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>361</vol-first>
<iss-first>9363</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1077</first-page>
<last-page>1083</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Anker, S.D., Negassa, A., Coats, A.J., Afzal, R., Poole-Wilson, P.A., Cohn, J.N., et al.: Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet. 361(9363), 1077–1083 (2003)</ref-fulltext>
<ce:source-text>Anker, S.D., Negassa, A., Coats, A.J., Afzal, R., Poole-Wilson, P.A., Cohn, J.N., et al.: Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet. 361(9363), 1077–1083 (2003)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Marinho</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Alcantara</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Ottoch</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Seelaender</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Marinho, R., Alcantara, P., Ottoch, J., Seelaender, M.: Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting. Front. Nutr. 4, 69 (2017)</ref-fulltext>
<ce:source-text>Marinho, R., Alcantara, P., Ottoch, J., Seelaender, M.: Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting. Front. Nutr. 4, 69 (2017)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Characterisation and Mechanisms of Altered Body Composition and Tissue Wasting in Cancer Cachexia</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<ref-text>University of Edinburgh</ref-text>
</ref-info>
<ref-fulltext>Miller, J.: Characterisation and mechanisms of altered body composition and tissue wasting in cancer cachexia. University of Edinburgh (2020)</ref-fulltext>
<ce:source-text>Miller, J.: Characterisation and mechanisms of altered body composition and tissue wasting in cancer cachexia. University of Edinburgh (2020)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Insights into the potential use of microRNAs as biomarker in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Anindo</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Yaqinuddin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Surg</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>443</first-page>
<last-page>449</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Anindo, M., Yaqinuddin, A.: Insights into the potential use of microRNAs as biomarker in cancer. Int. J. Surg. 10(9), 443–449 (2012)</ref-fulltext>
<ce:source-text>Anindo, M., Yaqinuddin, A.: Insights into the potential use of microRNAs as biomarker in cancer. Int. J. Surg. 10(9), 443–449 (2012)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs as potential biomarkers in cancer: Opportunities and challenges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Lan</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Jin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biomed. Res. Int</ref-sourcetitle>
</ref-info>
<ref-fulltext>Lan, H., Lu, H., Wang, X., Jin, H.: MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed. Res. Int. 125094</ref-fulltext>
<ce:source-text>Lan, H., Lu, H., Wang, X., Jin, H.: MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed. Res. Int. 125094</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Small RNAome profiling from human skeletal muscle: Novel miRNAs and their targets associated with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Narasimhan</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Greiner</ce:surname>
</author>
<author seq="5">
<ce:initials>O.</ce:initials>
<ce:surname>Bathe</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>405</first-page>
<last-page>416</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Narasimhan, A., Ghosh, S., Stretch, C., Greiner, R., Bathe, O., Baracos, V., et al.: Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J. Cachexia. Sarcopenia Muscle. 8(3), 405–416 (2017)</ref-fulltext>
<ce:source-text>Narasimhan, A., Ghosh, S., Stretch, C., Greiner, R., Bathe, O., Baracos, V., et al.: Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J. Cachexia. Sarcopenia Muscle. 8(3), 405–416 (2017)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>He</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Calore</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Londhe</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Canella</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Guttridge</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Croce</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4525</first-page>
<last-page>4529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W., Calore, F., Londhe, P., Canella, A., Guttridge, D., Croce, C.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111(12), 4525–4529 (2014)</ref-fulltext>
<ce:source-text>He, W., Calore, F., Londhe, P., Canella, A., Guttridge, D., Croce, C.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111(12), 4525–4529 (2014)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6, cancer and cachexia: Metabolic dysfunction creates the perfect storm</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>White</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Transl Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>280</first-page>
<last-page>285</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>White, J.: IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Transl Cancer Res. 6(2), 280–285 (2017)</ref-fulltext>
<ce:source-text>White, J.: IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Transl Cancer Res. 6(2), 280–285 (2017)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshikwa</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Takano</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Kouta</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Horikoshi</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Asakawa</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Kudoh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>15</iss-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>e17544</first-page>
<last-page>e17544</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshikwa, T., Takano, M., Kouta, H., Horikoshi, M., Asakawa, T., Kudoh, K.: Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol. Cancer. 36(15_suppl), e17544–e17544 (2018)</ref-fulltext>
<ce:source-text>Yoshikwa, T., Takano, M., Kouta, H., Horikoshi, M., Asakawa, T., Kudoh, K.: Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol. Cancer. 36(15_suppl), e17544–e17544 (2018)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>McLeod</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Alhayyani</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Szczepny</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Watkins</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3059</first-page>
<last-page>3066</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, A., McLeod, L., Alhayyani, S., Szczepny, A., Watkins, D., Chen, W., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–66 (2017)</ref-fulltext>
<ce:source-text>Miller, A., McLeod, L., Alhayyani, S., Szczepny, A., Watkins, D., Chen, W., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–66 (2017)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ramsey</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Talbert</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Ahn</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Bekaii-Saab</ce:surname>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Badi</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Bloomston</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pancreatology</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>80</first-page>
<last-page>87</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ramsey, M., Talbert, E., Ahn, D., Bekaii-Saab, T., Badi, N., Bloomston, P., et al.: Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 19(1), 80–87 (2019)</ref-fulltext>
<ce:source-text>Ramsey, M., Talbert, E., Ahn, D., Bekaii-Saab, T., Badi, N., Bloomston, P., et al.: Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 19(1), 80–87 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Bayliss</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Schuster</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Dragnev</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Rigas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Expert. Opin. Biol. Ther</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1663</first-page>
<last-page>1668</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bayliss, T., Smith, J., Schuster, M., Dragnev, K., Rigas, J.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. 11(12), 1663–1668 (2011)</ref-fulltext>
<ce:source-text>Bayliss, T., Smith, J., Schuster, M., Dragnev, K., Rigas, J.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. 11(12), 1663–1668 (2011)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Tournadre</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Pereira</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Dutheil</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Giraud</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Courteix</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Sapin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>639</first-page>
<last-page>646</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., et al.: Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J. Cachexia. Sarcopenia Muscle. 8, 639–646 (2017)</ref-fulltext>
<ce:source-text>Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., et al.: Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J. Cachexia. Sarcopenia Muscle. 8, 639–646 (2017)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Callaway</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Delitto</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>D’Lugos</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Patel</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Nosacka</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Delitto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1863</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Callaway, C., Delitto, A., D’Lugos, A., Patel, R., Nosacka, R., Delitto, D., et al.: IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy. Cancers. 11(12), 1863 (2019)</ref-fulltext>
<ce:source-text>Callaway, C., Delitto, A., D’Lugos, A., Patel, R., Nosacka, R., Delitto, D., et al.: IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy. Cancers. 11(12), 1863 (2019)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Antunes</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Ferreira</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Moreira-Goncalves</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>709</first-page>
<last-page>727</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Antunes, J., Ferreira, R., Moreira-Goncalves, D.: Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol. Med. 24(8), 709–727 (2018)</ref-fulltext>
<ce:source-text>Antunes, J., Ferreira, R., Moreira-Goncalves, D.: Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol. Med. 24(8), 709–727 (2018)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hall</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Griss</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Sanchez</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Sadek</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Tremblay</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages-text>e8307</pages-text>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hall, D., Griss, T., Ma, J., Sanchez, B., Sadek, J., Tremblay, A., et al.: The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol. Med. 10(7), e8307 (2018)</ref-fulltext>
<ce:source-text>Hall, D., Griss, T., Ma, J., Sanchez, B., Sadek, J., Tremblay, A., et al.: The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol. Med. 10(7), e8307 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Vanderveen</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Fix</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Carson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2017"/>
</ref-info>
<ref-fulltext>VanderVeen, B., Fix, D., Carson, J.: Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation. Oxidative Med. Cell. Longev. 2017;Article ID 3292087</ref-fulltext>
<ce:source-text>VanderVeen, B., Fix, D., Carson, J.: Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation. Oxidative Med. Cell. Longev. 2017;Article ID 3292087</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Novel molecular targets of muscle wasting in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>204</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Skipworth, R.: Novel molecular targets of muscle wasting in cancer patients. Curr. Opin. Clin. Nutr. Metab. Care. 22(3), 196–204 (2019)</ref-fulltext>
<ce:source-text>Miller, J., Skipworth, R.: Novel molecular targets of muscle wasting in cancer patients. Curr. Opin. Clin. Nutr. Metab. Care. 22(3), 196–204 (2019)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Brzeszczynska</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schlib</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Langen</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Schols</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Aging</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1690</first-page>
<last-page>1702</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brzeszczynska, J., Johns, N., Schlib, A., Degen, S., Langen, R., Schols, A., et al.: Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. Aging. 8(8), 1690–1702 (2016)</ref-fulltext>
<ce:source-text>Brzeszczynska, J., Johns, N., Schlib, A., Degen, S., Langen, R., Schols, A., et al.: Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. Aging. 8(8), 1690–1702 (2016)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Temel</ce:surname>
</author>
<author seq="2">
<ce:initials>A.P.</ce:initials>
<ce:surname>Abernethy</ce:surname>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Currow</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Friend</ce:surname>
</author>
<author seq="5">
<ce:initials>E.M.</ce:initials>
<ce:surname>Duus</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>519</first-page>
<last-page>531</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Temel, J.S., Abernethy, A.P., Currow, D.C., Friend, J., Duus, E.M., Yan, Y., et al.: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17(4), 519–531 (2016)</ref-fulltext>
<ce:source-text>Temel, J.S., Abernethy, A.P., Currow, D.C., Friend, J., Duus, E.M., Yan, Y., et al.: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17(4), 519–531 (2016)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Currow</ce:surname>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Temel</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Abernethy</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Milanowski</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Friend</ce:surname>
</author>
<author seq="6">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol. Off. J. Eur. Soc. Med. Oncol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1949</first-page>
<last-page>1956</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Currow, D., Temel, J.S., Abernethy, A., Milanowski, J., Friend, J., Fearon, K.C.: ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(8), 1949–1956 (2017)</ref-fulltext>
<ce:source-text>Currow, D., Temel, J.S., Abernethy, A., Milanowski, J., Friend, J., Fearon, K.C.: ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(8), 1949–1956 (2017)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Enobosarm and lean body mass in patients with non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Crawford</ce:surname>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Johnston</ce:surname>
</author>
<author seq="3">
<ce:initials>R.P.</ce:initials>
<ce:surname>Taylor</ce:surname>
</author>
<author seq="4">
<ce:initials>J.T.</ce:initials>
<ce:surname>Dalton</ce:surname>
</author>
<author seq="5">
<ce:initials>M.S.</ce:initials>
<ce:surname>Steiner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol. [Internet]</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<page-information>
<pages>
<first-page>32</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">http://meetinglibrary.asco.org/content/128938-144</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Crawford, J., Johnston, M.A., Taylor, R.P., Dalton, J.T., Steiner, M.S.: Enobosarm and lean body mass in patients with non-small cell lung cancer. J. Clin. Oncol. [Internet]. (2014) [cited 2017 May 15];32, 5s(suppl; abstr 9618). Available from: http://meetinglibrary.asco.org/content/128938-144</ref-fulltext>
<ce:source-text>Crawford, J., Johnston, M.A., Taylor, R.P., Dalton, J.T., Steiner, M.S.: Enobosarm and lean body mass in patients with non-small cell lung cancer. J. Clin. Oncol. [Internet]. (2014) [cited 2017 May 15];32, 5s(suppl; abstr 9618). Available from: http://meetinglibrary.asco.org/content/128938-144</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-authors>
<collaboration seq="1">
<ce:text>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US)</ce:text>
</collaboration>
</ref-authors>
<ref-sourcetitle>2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://clinicaltrials.gov/ct2/show/NCT02330926</ce:e-address>
</ref-website>
<ref-text>Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov</ref-text>
</ref-info>
<ref-fulltext>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015, Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov. 2015 [cited 2016 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02330926</ref-fulltext>
<ce:source-text>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015, Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov. 2015 [cited 2016 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02330926</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
</author>
<author seq="2">
<ce:initials>B.J.A.</ce:initials>
<ce:surname>Laird</ce:surname>
</author>
<author seq="3">
<ce:initials>T.R.</ce:initials>
<ce:surname>Balstad</ce:surname>
</author>
<author seq="4">
<ce:initials>G.B.</ce:initials>
<ce:surname>Stene</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Bye</ce:surname>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
</ref-info>
<ref-fulltext>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Stene, G.B., Bye, A., Johns, N., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. (2017) Jun 14</ref-fulltext>
<ce:source-text>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Stene, G.B., Bye, A., Johns, N., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. (2017) Jun 14</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Hellerstein</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Orwoll</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Cummings</ce:surname>
</author>
<author seq="5">
<ce:initials>P.M.</ce:initials>
<ce:surname>Cawthon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
<last-page>21</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Hellerstein, M., Orwoll, E., Cummings, S., Cawthon, P.M.: D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J. Cachexia. Sarcopenia Muscle. 10(1), 14–21 (2019)</ref-fulltext>
<ce:source-text>Evans, W.J., Hellerstein, M., Orwoll, E., Cummings, S., Cawthon, P.M.: D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J. Cachexia. Sarcopenia Muscle. 10(1), 14–21 (2019)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Costa</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Caro</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>de Matos-Neto</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Lima</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Radloff</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Alves</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1116</first-page>
<last-page>1127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costa, R., Caro, P., de Matos-Neto, E., Lima, J., Radloff, K., Alves, M., et al.: Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J. Cachexia. Sarcopenia Muscle. 10(5), 1116–1127 (2019)</ref-fulltext>
<ce:source-text>Costa, R., Caro, P., de Matos-Neto, E., Lima, J., Radloff, K., Alves, M., et al.: Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J. Cachexia. Sarcopenia Muscle. 10(5), 1116–1127 (2019)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Gut Microbes</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>189</first-page>
<last-page>200</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morrison, D., Preston, T.: Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 7, 189–200 (2016)</ref-fulltext>
<ce:source-text>Morrison, D., Preston, T.: Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 7, 189–200 (2016)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>The immunological regulation of cancer cachexia and its therapeutic implications</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Laird</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Metastasis Treat</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>68</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Laird, B., Skipworth, R.: The immunological regulation of cancer cachexia and its therapeutic implications. J. Cancer Metastasis Treat. 5, 68 (2019)</ref-fulltext>
<ce:source-text>Miller, J., Laird, B., Skipworth, R.: The immunological regulation of cancer cachexia and its therapeutic implications. J. Cancer Metastasis Treat. 5, 68 (2019)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Roberts</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Deonarine</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Jones</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Denton</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Feig</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Lyons</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Med</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>210</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1137</first-page>
<last-page>1157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roberts, E., Deonarine, A., Jones, J., Denton, A., Feig, C., Lyons, S., et al.: Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 3(210), 1137–1157 (2013)</ref-fulltext>
<ce:source-text>Roberts, E., Deonarine, A., Jones, J., Denton, A., Feig, C., Lyons, S., et al.: Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 3(210), 1137–1157 (2013)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Doan</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Sin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>589</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H., Sin, K., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(589) (2017)</ref-fulltext>
<ce:source-text>Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H., Sin, K., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(589) (2017)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Burfeind</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Zhu</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Levasseur</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Michaelis</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Norgard</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Marks</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Brain Behav. Immun</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>73</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>364</first-page>
<last-page>374</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Burfeind, K., Zhu, X., Levasseur, P., Michaelis, K., Norgard, M., Marks, D.: TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia. Brain Behav. Immun. 73, 364–374 (2018)</ref-fulltext>
<ce:source-text>Burfeind, K., Zhu, X., Levasseur, P., Michaelis, K., Norgard, M., Marks, D.: TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia. Brain Behav. Immun. 73, 364–374 (2018)</ce:source-text>
</reference>
</bibliography>
</tail>

</bibrecord>


</unit-content>
</unit>
</units>